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Abstract 
 
Cancers of virtually all types exhibit not only genetic abnormalities but also 
epigenetic ones which consist of DNA methylation and chromatin alterations. Among the 
key cancer specific changes involving interplay of these epigenetic parameters are 
simultaneous wide spread losses of DNA methylation and more focal gains at CpG rich, 
proximal promoter regions and/or CpG islands. The latter change can associate with 
abnormal gene silencing and loss of gene function. These DNA methylation changes 
arise early in cancer risk states and early phases of tumor initiation, and may be important 
drivers of these processes. One key risk state for neoplastic transformation is chronic 
inflammation and oxidative stress, including stress generated during metabolic events. By 
exposing cells to hydrogen peroxide (H2O2) to mimic acute increase in reactive oxygen 
species, we demonstrate that, in addition to the known function of this insult for inducing 
DNA mutagenesis, oxidative damage can induce important epigenetic alterations in 
multiple cell line models, including the above changes in DNA methylation.  
Upon H2O2 treatment, DNA methyltransferase 1 (DNMT1), the main enzyme for 
maintaining DNA methylation on newly replicated DNA, and sirtuin 1 (SIRT1), a NAD+-
dependent class III histone deacetylase, become more tightly bound to chromatin. SIRT1, 
a key player in epigenetic gene silencing and DNA damage repair, is involved in a 
transformation specific polycomb complex, polycomb repressive complex 4 (PRC4). 
Other components of PRC4 include enhancer of zeste homolog 2 (EZH2), which 
catalyzes the repressive histone modification, trimethylation of lysine 27 of histone H3. 
DNMT1, DNMT3B, one of the de novo DNA methyltransferases, and components of 
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PRC4 coexist in a large silencing complex(es). With H2O2 treatment, the size and 
abundance of this complex(es) increase. Co-immunofluorescence experiments indicate 
that this complex(es) resides, at least in part, at DNA damage foci. Through further 
genome-wide and local chromatin immunoprecipitation analyses, we show that 
constituents of this oxidative damage induced complex(es) concurrently translocate from 
transcriptionally inactive to active chromosome regions and from non-GC-rich to GC-
rich areas, including promoter CpG islands, within 30 minutes of H2O2 exposure. 
Accompanying the above re-localization, several functional consequences are 
observed. First, after treatment, there is reduction in the active histone marks, H3K4Me3 
and H4K16Ac, and enrichment of the repressive H3K27Me3 mark at regions most 
targeted by members of the complex(es), for example, the active CpG island-containing 
gene promoters; whereas opposing trends are observed at low expression non-CpG island 
gene promoters. Second, there is reduction in the nascent transcription levels of the active 
CpG island-containing genes, MYC, ACTB, TIMP3, and MLH1 within 30 minutes of 
treatment. In contrast, the repressive non-CpG island-containing genes, NANOG, HBD, 
and IL8, either gain or have no change in their nascent transcription levels. Third, it is 
found that genes targeted by the complex(es) often develop cancer-specific, abnormal, 
CpG island DNA hypermethylation during tumorigenesis. Indeed, several genes, such as 
MLH1, SFRP5, and SFRP4, show increased promoter CpG island DNA methylation, as 
determined by bisulfite sequencing after H2O2 treatment.  
All of the above data provide a possible mechanism for abnormal changes in 
transcription and histone modifications often observed in cancer, and helps to explain the 
conundrum in the abnormalities of DNA methylation in cancer, namely, why cancer cells 
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simultaneously harbor both widespread chromosomal loss of DNA methylation and 
increased DNA methylation in CpG islands of gene promoters. More excitingly, some of 
the above observations were also validated by an in vivo colitis model, further 
strengthening the physiologic significance of our findings in cancer risk states, such as 
chronic inflammation. 
A second series of studies were focused on the fact that aberrant epigenetic changes 
are more easily reversed by pharmacological interventions as compared to genetic 
mutations. Thus, increasing efforts are being exerted to develop preclinical and clinical 
studies of epigenetic drugs. Among these, the most studied are various DNA 
demethylating agents, such as 5-aza-cytidine (5-Aza-CR), and histone deacetylase 
inhibitors, such as Entinostat. A recent clinical trial with low dose 5-Aza-CR plus 
Entinostat has shown true therapeutic promise in patients with heavily pre-treated non-
small cell lung cancer (NSCLC). To help understand this, we matched genome-wide 
DNA methylation and gene expression responses to 5-Aza-CR in eight NSCLC cell lines 
with basal levels of these parameters in the Cancer Genome Atlas (TCGA) project. 
The response signature for the cell line with the most robust anti-tumor response, 
based on a ex vivo model, clusters with a small group of TCGA lung squamous tumors, 
and couples low expression and DNA hypermethylation of RASSF1 with gene expression 
changes suggesting high cell cycle entry and stem cell pathway activity and low apoptotic 
capacity by pathway analyses. This suggests effective biomarker strategies to identify the 
best candidate patients for response to epigenetic therapy. 
Meanwhile, the general response signature for all the eight cell lines, clusters with 
larger groups of TCGA tumors, and points to a reversal of a complex tumor immune 
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evasion signature, closely tied to interferon response pathways as analyzed by multiple 
pathway programs and gene set enrichment analysis (GSEA). A clue to the role of the 
drug in this process is that in some of the NSCLC lines, 5-Aza-CR induces the up-
regulation of IRF7, a transcription factor for the interferon pathway, whose CpG island 
DNA hypermethylation and low expression tracks the immune evasion signature. FACS 
analysis also shows increased cell surface presence of PD-L1, an essential target for 
therapy to inhibit immune tolerance, by 5-Aza-CR treatment. These findings all suggest 
that epigenetic therapy may provide subsequent sensitization to therapy targeting immune 
tolerance checkpoints. In fact, in a trial of such immunotherapy, all 5 patients who 
happened to receive such therapy subsequent to 5-Aza-CR treatment have shown 
treatment benefit lasting at least 24 weeks, and three of the five patients have experienced 
major responses by RECIST criteria to subsequent immunotherapy, all of which are 
ongoing from 18 to 24+ months. We suggest this kind of pre-clinical, genomics based, 
approach could help efficient identification of patients who will receive maximum benefit 
from a breaking immune tolerance therapy given after epigenetic therapy. A larger trial 
has just started to test this hypothesis and many parameters of our above pre-clinical 
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1.1 Epigenetics 
 
The prefix “epi-”, derived from Greek, means “in addition to”. Thus, it is easy to 
understand “epigenetics” as referring to phenotypes associated with mechanisms other 
than those inherited genetically. Since the invention of this word by British scientist C. H. 
Waddington in 1942 (Waddington, 2012), the definition of epigenetics has been modified 
by many others, including Robin Holliday, Arthur Riggs, and Adrian Bird et al. A recent 
consensus definition of epigenetics was achieved at the 2008 Cold Spring Harbor meeting, 
as the “stably heritable phenotype resulting from changes in a chromosome without 
alterations in the DNA sequence” (Berger et al., 2009). 
Common epigenetic mechanisms of gene expression regulation include, but are not 
limited to, DNA methylation, chromatin remodeling, and histone modifications. 
Coordinately, these mechanisms define the epigenetic landscape of cells, from the time of 
embryogenesis through adult cell renewal, which establish their different phenotypes 
despite their having identical genetic information. The heritably of the epigenetic control 
can then be maintained through generations of cell division.  
Abnormality in the control of any of these epigenetic mechanisms can cause severe 
consequences, which can manifest during development and in diseases such as cancer. It 
has been shown that epigenetic aberrations at both individual gene levels and on a 
genome-wide scale can underlie these abnormalities. Identifying these aberrations and 
fully understanding these epigenetic mechanisms will significantly aid in management of 
diseases such as for the detection and treatment of cancer. 
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1.1.1 DNA methylation 
Biological functions 
DNA methylation is found in the genomes of organisms ranging from prokaryotes to 
eukaryotes. In prokaryotes, DNA methylation occurs on both cytosine and adenine bases 
and constitutes part of the host restriction system (Wilson and Murray, 1991). In 
multicellular eukaryotes, however, the majority of DNA methylation is confined to 
cytosine bases and is associated with a condensed chromatin state and repression of gene 
expression (Bird, 2002). This methylation, for cytosine, is catalyzed by a family of 
enzymes named DNA methyltransferases (DNMTs) and involves the transfer of a methyl 
group from a S-adenosyl methionine donor, to the 5’ position of the pyrimidine ring of 
cytosine (Cheng and Blumenthal, 2008). In humans, the methylation of cytosine usually 
occurs at CpG dinucleotides (Bird, 1980). It is well established that this methylation in 
gene proximal promoter regions is typically associated with transcriptional repression, 
whereas the methylation of gene bodies correlates with transcriptional activity, probably 
secondary to facilitation of transcriptional elongation (Varley et al., 2013). Through such 
dynamics, 5-methylcytosine modulates multiple biological processes including 
embryonic development, gene imprinting, often gene silencing but also gene activation in 
some circumstances as mentioned, and the structural integrity of chromosomes (Bird, 
2002). 
DNA methylation is not distributed evenly in the mammalian genome. The CpG 
dinucleotide is under-represented in the human genome due to, over evolution, the high 
mutation rate of 5-methylcytosine to thymine (Bird, 1986). Thus, the remaining CpG 
sites are heavily DNA methylated in the human genome (Bird, 1986). The exception is so 
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called “CpG islands”, defined as GC-rich regions (GC content ≥ 55%) of 500 base pairs 
(bp) or longer that possess high densities of CpG dinucleotides (observed to expected 
CpG ratio ≥ 0.65) (Takai and Jones, 2002). Computational genome analysis predicts the 
existence of ~29,000 CpG islands in the human genome associated with ~60% of gene 
promoters (Antequera and Bird, 1993; Venter et al., 2001). The majority of these 
promoter CpG islands are unmethylated at all developmental stages in all tissue types 
(Antequera and Bird, 1993). A small proportion of these CpG islands become methylated 
during development and are associated with stable gene silencing. Such silencing, on an 
individual allele associated basis, is developmentally programmed for allelic retention of 
CpG-island methylation especially for genomic imprinting and X chromosome 
inactivation (Bird, 1993). De novo DNA methylation occurs in germ cells or the early 
embryo (Jaenisch et al., 1982), suggesting that it is particularly active at these stages. In 
addition, de novo DNA methylation can also occur in the aging process of adult somatic 
cells. A significant proportion of human CpG islands are prone to progressive 
methylation during aging (Issa, 2000), or in abnormal cells such as cancer cells (Baylin 
and Herman, 2000; Plass et al., 2013; Shen and Laird, 2013).  
Although DNA methylation predominately occurs at CpG dinucleotides in the human 
genome, there have been some reports that non-CpG cytosine methylation exists in 
embryonic and pluripotent cells. First, high-throughput sequencing of bisulphite treated 
DNA showed that in human embryonic stem (ES) cells 25% of 5-methylcytosine was in a 
non-CpG context, whereas in fetal lung fibroblast cell line IMR90 only 0.02% of 
methylcytosine was in a non-CpG context, despite overall amounts of CpG methylation 
being similar (Lister et al., 2009). Cytosine methylation in non-CpG contexts shows 
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enrichment in gene bodies, with the level of methylation positively correlating with gene 
expression levels (Lister et al., 2009). The ENCODE project found that non-CpG 
methylation also exists in somatic cells, especially in the brain (Varley et al., 2013). The 
biological function and molecular mechanism of non-CpG methylation are not clear and 
are worth future investigation. 
Multiple lines of evidence support the idea that the major biological function of DNA 
methylation is to regulate chromatin structure. The most compelling evidence for this 
idea comes from DNA transfection studies showing that unmethylated DNA substrates 
are packaged into an open chromatin structure following their integration into the genome 
and are sensitive to DNase I treatment, whereas the same DNA remains completely 
resistant to DNase I treatment if it is methylated (Keshet et al., 1986). Currently, the 
molecular mechanism by which DNA methylation regulates chromatin packaging is 
unclear. Early experiments indicated that most methylated CpG dinucleotides are 
concentrated within the central core of nucleosomes, as opposed to inter-nucleosomal 
regions, suggesting that the positioning of methylated CpG dinucleotides may have an 
intrinsic effect on where nucleosomes reside on the DNA (Razin and Cedar, 1977; Solage 
and Cedar, 1978), and these results have recently been confirmed by sophisticated 
genome-wide analysis (Chodavarapu et al., 2010). Another way DNA methylation 
mediates chromatin structure is through methyl-binding proteins, such as MBD2. These 
proteins specifically recognize methylated CpG dinucleotide and remodel local chromatin 
structure through recruiting histone deacetylases HDAC1/2 or histone demethylase LSD1 
(Lai and Wade, 2011). Alternatively, DNA methylation may block the binding of 
chromatin proteins such as chromatin boundary factor CTCF or Cfp1, which are known 
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to exclusively bind unmethylated CpG islands (Bell and Felsenfeld, 2000; Thomson et al., 
2010). These results provide important insights into the mechanism of epigenetic gene 
silencing mediated by DNA methylation. 
Mechanisms for establishing 
DNA methylation is a post-synthetic modification (Burdon and Adams, 1969; 
Scarano et al., 1965). As previously mentioned, this process is catalyzed by a family of 
enzymes known as DNMTs. In mammals, four DNMTs have been identified, with 
different roles in the establishment and maintenance of DNA methylation (Bird, 2002).  
DNMT1 has the ability to copy the methylation pattern from one strand to another 
and has led to DNMT1 being known as the maintenance methyltransferase. It was 
thought that DNMT1 allows the faithful replication of the 5-methylcytosine marks onto 
the newly synthesized DNA strand through its association with the master regulator 
protein of DNA replication, PCNA (Chuang et al., 1997). However, recent work revealed 
that UHRF1 is the major protein which targets DNMT1 to hemi-methylated DNA 
(Bostick et al., 2007; Sharif et al., 2007). In addition, DNA methylation is well 
maintained in a DNMT1 hypomorph of human colon cancer cell line HCT116 which 
express a truncated DNMT1 isoform without its PCNA binding motif (Egger et al., 2006). 
The importance of DNMT1 protein can be inferred from the lethality of the Dnmt1 
knockout mouse (Li et al., 1992) and the lethal effect of DNMT1 complete knockout in 
human colon cancer cell line HCT116 (Chen et al., 2007). Both the DNMT1 knockout 
mouse and ES cells show approximately 70% reduction in 5-methylcytosine. Although 
DNMT1 knockout ES cells are viable, the DNMT1 knockout mouse is embryonic lethal 
and embryos are stunted and die at midgestation (Li et al., 1992). DNMT1 has been 
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shown to interact with histone methyltransferase G9a and histone deacetylases HDAC1/2, 
raising the possibility that DNMT1 functions, in addition to catalyzing DNA methylation, 
as a scaffold protein to recruit other epigenetic modifier proteins to modulate local 
chromatin states (Robertson et al., 2000; Rountree et al., 2000).  
Through searching for human proteins that were homologous to bacterial DNA 
methyltransferases, de novo DNA methyltransferases DNMT3A and 3B were discovered 
(Okano et al., 1998). These two proteins were most highly expressed in ES cells and in 
vitro DNA methylation studies showed that recombinant DNMT3A and DNMT3B 
proteins act on non-methylated DNA and had no preference for hemi-methylated DNA 
(Okano et al., 1998). Genetic knockouts of Dnmt3a and 3b in mouse ES cells indicated 
that, in the absence of both proteins, there was a loss of de novo DNA methylation, but 
single knockouts still maintained de novo DNA methylation activity, suggesting that 
DNMT3A and DNMT3B have redundant functions (Okano et al., 1999). Methylation 
analysis of the genomic DNA from single DNMT3 knockout ES cells revealed that loss 
of Dnmt3a resulted in hypomethylation of major satellite repeats and a loss of some 
maternal imprints, whereas loss of Dnmt3b led to hypomethylation of minor satellite 
repeats (Chen et al., 2003; Okano et al., 1999). This result suggested that DNMT3A and 
DNMT3B target different genomic regions.  
Although DNMT1 is thought to be the maintenance DNMT, there is some evidence 
that DNMT3A and DNMT3B also participate in DNA methylation maintenance. 
Extended culture of Dnmt3a/3b double knockout ES cells led to a progressive loss of 
methylation to levels approaching that of Dnmt1 knockout ES cells (Chen et al., 2003). 
Overall, this suggests that both DNMT3A and 3B are required in concert with DNMT1 
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for the maintenance of DNA methylation, arguing against the simple model of 
“maintenance” and “de novo” methyltransferases (Bird, 2002). For this reason, Peter 
Jones suggested a new model in which all three DNMTs work in concert to maintain 
methylation patterns with DNMT3A and 3B helping to fill in methylation gaps left by 
DNMT1 (Jones and Liang, 2009).  
Recently, hydroxymethylation at the C-5 position of cytosine in the context of CpG 
dinucleotides was observed in vertebrate genomes (Tahiliani et al., 2009). In contrast to 
5-methylcytosine which is catalyzed by DNMTs, the conversion of 5-methylcytosine to 
5-hydroxymethylcytosine is catalyzed by the TET (ten-eleven translocation proteins or 
methylcytosine dioxygenases) family of enzymes (Tahiliani et al., 2009). 5-
hydroxymethylcytosine can be converted back to unmodified cytosine either passively or 
actively resulting in DNA demethylation (Pfeifer et al., 2013). This is currently the only 
known method for active DNA demethylation. However, final conversion of 5-
hydroxymethylcytosine back to cytosine requires additional DNA repair mediated steps 
and these can act, also, in concert for conversion of 5-methylcytosine back to cytosine 
(Bhutani et al., 2011; Piccolo and Fisher, 2013). Recent results suggested that 5-
hydroxymethylcytosine might also mediate transcriptional repression through the 
recruitment of methyl-binding protein MBD3 (Yildirim et al., 2011). 
 
1.1.2 Chromatin remodeling 
In eukaryotes, DNA is packaged into basic structure units, called nucleosomes. From 
a linear standpoint, each nucleosome core particle encompasses a segment of DNA of 
about 147bp wrapped around a histone octamer, consisting of pairs of each histone core 
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proteins, H2A, H2B, H3, and H4, or their variants (Lilley and Pardon, 1979; McGhee and 
Felsenfeld, 1980). Nucleosome core units are connected by linker DNA of various 
lengths and the linker histone protein H1 and then compacted into higher order chromatin 
structures (Felsenfeld and McGhee, 1986; Struhl and Segal, 2013). When this packing is 
tight and highly organized, the landscape is termed heterochromatin and is associated 
with a transcriptionally repression state (Fahrner and Baylin, 2003; Wutz, 2011). In 
contrast, euchromatin represents areas of much less tightly packed DNA with often 
nucleosome free regions termed as relatively open chromatin and this is often associated 
with active transcription (Bassett et al., 2009; Lamond and Earnshaw, 1998).  
The dynamic balance between tight and more open chromatin packaging is important 
for epigenetic regulation of gene expression (Bassett et al., 2009). Chromatin dynamics 
involves interaction among histones, histone chaperone proteins, histone modification 
enzymes, and a group of chromatin remodeling complexes (remodelers) (Allis et al., 
2007; Khorasanizadeh, 2004). Chromatin remodelers use the energy of ATP hydrolysis to 
change the packaging state of the nucleosome which is the primary structure unit of 
chromatin and to regulate where it is located (Clapier and Cairns, 2009). Remodelers 
cooperate with other chromatin factors to regulate the packaging and unpackaging of 
genomic regulatory DNA elements including enhancers, promoters, replication origins 
that are essential for biological processes such as gene transcription, DNA replication and 
DNA repair (Altmeyer and Lukas, 2013; Fadloun et al., 2013; Soria et al., 2012). 
Therefore, chromatin structure becomes a key platform for regulation of gene expression. 
Four major types of chromatin remodeler families and their biological functions in gene 
repression, DNA damage and DNA repair are listed below.  
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 SWI family remodelers. The SWI/SNF (switching defective/sucrose nonfermenting) 
family of remodelers was first characterized in Saccharomyces cerevisiae and 
contains 8 to 14 protein subunits. This family of remodelers has many activities 
including sliding and ejecting nucleosomes at many genomic loci (Mohrmann and 
Verrijzer, 2005). 
 ISWI family remodelers. The ISWI (imitation switch) family of remodelers contains 
2 to 4 protein subunits. dNURF, dCHRAC, and dACF complexes were originally 
identified in Drosophila melanogaster, with hWICH or hNoRC characterized in 
human subsequently. Many ISWI family complexes (ACF, CHRAC) optimize 
nucleosome spacing to promote chromatin assembly and repress transcription. 
However, some ISWI complexes (NURF) can randomize spacing, which can activate 
transcription (Corona and Tamkun, 2004). 
 CHD family remodelers. The CHD (chromodomain, helicase, DNA binding) family 
of remodelers is composed of 1 to 10 protein subunits and was initially purified 
from Xenopus laevis (Marfella and Imbalzano, 2007). Certain CHD remodelers slide 
or eject nucleosomes to promote transcription. However, others have repressive roles, 
including the vertebrate Mi-2/NuRD (nucleosome remodeling and deacetylase) 
complex, which contains two histone deacetylases (HDAC1/2) and two methyl CpG-
binding domain proteins, MBD2 and MBD3 (Denslow and Wade, 2007).  
 INO80 family remodelers. The INO80 (inositol requiring 80) family of remodelers 
contains more than 10 protein subunits and was first characterized 
from Saccharomyces cerevisiae (Bao and Shen, 2007). Its higher orthologs include 
hINO80 and p400, which also contains histone acetyltransferase activity. INO80 
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family of remodelers has multiple biological functions including promoting 
transcriptional activation and DNA repair (Min et al., 2013).  
The general mechanism for chromatin remodelers to repress transcription is to help 
genomic regions assemble into nucleosome arrays, restricting the access of DNA-binding 
transcription factors (Hargreaves and Crabtree, 2011; Narlikar et al., 2013). Furthermore, 
remodelers also cooperate with HDAC to repress transcription repression (Marks et al., 
2001). For example, the chromatin remodeling complex NuRD contains histone 
deacetylases HDAC1 and HDAC2, and a methyl-DNA binding protein (MBD2) for 
recognizing DNA methylation, strongly supporting its role in the maintenance of gene 
silencing in methylated genomic regions (Clapier and Cairns, 2009). Another good 
example is the NoRC complex, which mediates rDNA silencing through its recruitment 
to the RNAPI promoters by TTF-I (Strohner et al., 2004); then NoRC remodels the 
promoter-bound nucleosome to a position unfavorable for transcription and recruits 
HDAC and DNMTs in an H4K16ac-dependent manner (Li et al., 2006). Finally, the S. 
pombe SHREC complex is important for the assembly of silent pericentromeric 
heterochromatin (Sugiyama et al., 2007).  
 
1.1.3 Histone modifications 
The N-terminal tails of histone proteins are freely extended from the core structure 
and are actively subjected to covariant modifications, such as methylation, acetylation, 
phosphorylation, ubiquitination, and sumoylation (Berger, 2002; Jenuwein and Allis, 
2001). The type and position of each histone modification, and the cross-talk between 
different modifications can uniquely alter protein-DNA and protein-protein interactions 
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that affect chromatin configuration and recruitment of other chromatin-binding proteins, 
thus impacting gene expression in either an active or repressive manner (Strahl and Allis, 
2000; Zhang and Reinberg, 2001). Therefore, the modifications of histones establish 
another layer of epigenetic code, the histone code (Jenuwein and Allis, 2001; Wang et al., 
2004). 
Some of the most commonly studied histone modifications include: the trimethylation 
of lysine 4 on histone H3 (H3K4Me3), acetylation of lysine 9 and lysine 14 on histone 
H3 （H3K9Ac and H3K14Ac), and acetylation of lysine 16 on histone H4 （H4K16Ac), 
are specially enriched at actively transcribed gene promoters (Eissenberg and Shilatifard, 
2010; Graff and Tsai, 2013; Zentner and Henikoff, 2013). The trimethylation of lysine 36 
on histone H3 (H3K36Me3) is usually found at actively transcribed gene bodies (Wagner 
and Carpenter, 2012). In contrast, the trimethylation of lysine 9 on histone H3 (H3K9me3) 
is highly correlated with constitutive heterochromatin and the trimethylation of lysine 27 
on histone H3 (H3K27me3) is frequently observed at transcriptionally repressed gene 
promoters and is heavily enriched at facultative heterochromatin (Bracken and Helin, 
2009; Shinkai and Tachibana, 2011). Sometimes, proximal promoter chromatin domains 
can be marked by both the active H3K4me3 mark and the repressive H3K27me3 mark, 
forming so-called bivalent chromatin (Bernstein et al., 2006; Ohm et al., 2007). Such 
chromatin domains are especially prominent in ES cells (Johnson et al., 2012; Marks et 
al., 2012). Genes which are so marked, constituting ~ 2500 in ES cells, are often poised 
for activation of transcription, giving the possibility to rapidly alter to fully active or 
silenced states with differentiation of ES cells into distinct lineages as necessary 
(Bernstein et al., 2006; Spivakov and Fisher, 2007). These genes that are bivalently 
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marked in ES cells are often the targets of polycomb repressive complexes in adult stem 
cells and have a higher tendency to be aberrantly silenced by DNA hypermethylation in 
cancer (Easwaran et al., 2012; Ohm et al., 2007; Widschwendter et al., 2007). 
Numerous enzymes are involved in applying and removing of specific type of histone 
modifications. The acetylation and deacetylation of lysine are quite dynamic and carried 
out by two large families of enzymes, histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), respectively (Bannister and Kouzarides, 2011; Zentner and 
Henikoff, 2013). One the other hand, enzymes involved in the regulation of methylation 
of lysine, histone lysine methyltransferases (HKMT) and histone demethylases (HDMs), 
have greater substrate specificity (Bannister and Kouzarides, 2011; Zentner and Henikoff, 
2013). For example, SETD7 specifically monomethylates lysine 4 on histone H3, and 
KDM4C demethylates H3K9Me3 but not H3K9Me or H3K9Me2 (Berry and Janknecht, 
2013; Wagner and Jung, 2012). 
In addition, there are specific histone modifications which accompany DNA damage 
and repair processes (Price and D'Andrea, 2013). When DNA damages occur in the 
genome, a rapid cellular response is the phosphorylation of serine 129 of H2A in yeast or 
serine 139 of H2A.X in vertebrates (Xiao et al., 2009). This histone modification helps 
recruit DNA repair factors as well as chromatin remodelers of the SWI/SNF and INO80 
families which facilitate the access of DNA repair enzymes to the DNA damage sites 
(Lukas et al., 2011; Xiao et al., 2009). Therefore, the phosphorylation of H2A/H2A.X 
provides a good system for the rapid recognition of DNA damage sites followed with 
efficient repair.  
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1.2 Epigenetics in Cancer 
 
In addition to genetic mutations and chromosome translocations, aberrant epigenetic 
regulation is often observed in cancer and is a significant contributor to tumorigenesis 
(Jones and Baylin, 2007). Aberrant activation of oncogenes could be a direct trigger for 
tumorigenesis, whereas epigenetic silencing of commonly expressed tumor suppressor 
genes can provide for loss of function of these genes (Baylin and Bestor, 2002). These 
abnormalities often occur in the setting of one of the key features of cancer cells, 
abnormal DNA-methylation patterns which include gain of methylation 
(hypermethylation) and loss of methylation (hypomethylation) (Feinberg, 2007). It is well 
established that cancer progression associates with a decrease of overall DNA 
methylation and an increase in the methylation of CpG islands located in the promoter 
regions of many tumor suppressor genes (Jones and Baylin, 2007). Recently, the 
ENCODE project did a base-resolution mapping of methylcytosine across 82 cell lines 
including both normal and cancer cells (Varley et al., 2013). This study discovered that 
there are 66,570 CpGs hypermethylated in cancer cells, including cell lines derived from 
breast, prostate, lung, ovarian, endometrial, liver, and pancreatic cancer, as well as 
neuroblastoma and several leukemias. Among these hypermethylated CpGs, 48,787 (73%) 
reside in CpG islands (Varley et al., 2013). The observation of cancer-specific CpG 
islands hypermethylation across the genome in multiple cancer cell lines is consistent 
with reports of a CpG island methylator phenotype (CIMP) that was first described in 
colorectal cancer (Toyota et al., 1999) and later documented in many other cancer types 
(Chen et al., 2012; Liu et al., 2011; Teodoridis et al., 2008; Turcan et al., 2012). An 
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additional 7377 (11%) non-island CpGs are significantly hypermethylated in cancer, and 
these reside in promoters and bodies of genes encoding proteins with sequence-specific 
DNA binding transcription factor activity (Varley et al., 2013). DNA hypermethylation in 
both the promoter and gene body of these transcription factor genes indicates 
dysregulation of methylation at these genes in various cancers. Chapter 2 of this thesis 
focuses on revealing the underline mechanisms of aberrant epigenetic silencing during 
tumorigenesis in a special background of oxidative stress which is common many cancer 
risk states, such as chronic inflammation. 
 
1.3 Epigenetic Therapy 
 
Epigenetic silencing of tumor suppressor genes is a general phenomenon during 
tumorigenesis in virtually all types of cancer (Esteller et al., 2001; Herman and Baylin, 
2003; Jones and Baylin, 2007; Santini et al., 2001). Unlike genetic mutations, epigenetic 
alterations are pharmacologically reversible, which makes them attractive targets in 
cancer management (Issa and Kantarjian, 2009). Many compounds have been developed 
to specifically target proteins that control DNA methylation and histone modifications. 
Among them, two important DNA demethylating agents, 5-aza-cytidine and 5-aza-2'-
deoxycytidine, have been of great interest. 
5-aza-cytidine and 5-aza-2'-deoxycytidine were first synthesized in the 1960s as 
cytidine analogues. Once they are transported into the cells, they can be incorporated into 
DNA (5-aza-cytidine and 5-aza-2'-deoxycytidine) and RNA (5-aza-cytidine) after 
multiple phosphorylation steps (Oki et al., 2007). These drugs can form a covalent 
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complex with DNMTs, therefore inhibit the enzymatic activities of DNMTs and lead to 
DNA demethylation (Jones and Taylor, 1980; Jones and Taylor, 1981). Multiple reports 
indicated that 5-aza-cytidine and 5-aza-2'-deoxycytidine were able to induce durable 
complete remission in hematological malignancies, especially in myelodysplastic 
syndrome (MDS) at low doses (Cashen et al., 2010; Issa et al., 2004; Kantarjian et al., 
2003; Wijermans et al., 2000). These results were further confirmed by larger clinical 
trials (Kantarjian et al., 2006; Silverman et al., 2002). Based on their promising clinical 
efficacy, 5-aza-cytidine and 5-aza-2'-deoxycytidine were approved by U.S. Food and 
Drug Administration (FDA) in 2004 and 2006 respectively for the treatment of MDS and 
have now become a standard care option for patients with high risk MDS. 
The achievement of high clinical efficacy and low toxicity with low dose regimens 
opened more opportunities for the drugs. Mild toxicity profiles of the drugs at low doses 
enable clinicians to explore the possibility of combination therapies with other 
epigenetic-modifying agents, such as HDAC inhibitors, or with other chemotherapeutic 
agents or immunotherapeutic agents in both hematological malignancies and solid tumors 
(de Vos and van Overveld, 2005; Gore, 2005; Groselj et al., 2013). Numerous clinical 
trials are currently under-going and give us a promise for new therapy concepts aimed to 
markedly improve cancer management. Chapter 3 of this thesis focuses on pre-clinical 
work aimed at understanding the molecular basis of anti-tumor responses for the DNA 
demethylating agents discussed above, with an aim to develop biomarkers which predict 
efficacy.  
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Reprint from: Oxidative damage targets complexes containing DNA methyltransferases, 
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2.1 Summary 
 
Cancer cells simultaneously harbor global losses and gains in DNA methylation. We 
demonstrate that inducing cellular oxidative stress by treatment with hydrogen peroxide, 
recruits DNA methyltransferase 1 (DNMT1) to damaged chromatin. DNMT1 becomes 
part of a complex(es) containing DNMT3B and members of Polycomb Repressive 
Complex 4. Hydrogen peroxide treatment causes translocalization of these proteins from 
non-GC-rich to GC-rich areas. Key components are similarly enriched at gene promoters 
in an in vivo colitis model. While high expression genes enriched for members of the 
complex have histone mark and nascent transcription changes, CpG island-containing 
low expression genes gain promoter DNA methylation. Thus, oxidative damage induces 
formation and localization of a silencing complex that may explain cancer-specific 
aberrant DNA methylation and transcriptional silencing.  
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2.2 Significance 
 
Tumors have aberrant gains and losses in DNA methylation, although the 
mechanisms establishing these changes are not well understood. Here we demonstrate 
that oxidative damage induces the formation of a large silencing complex(es) containing 
DNA methyltransferases and constituents of the polycomb complex, PRC4, including 
SIRT1. PRC4 is found uniquely in cancer and embryonic and adult stem cells. Key 
constituents of the damage-induced complex are recruited from transcriptionally poor 
regions of the genome to GC-rich areas, including promoter CpG islands. Such 
translocalization causes changes in histone marks, transcription, and DNA methylation. 
We suggest that this re-localization may be a mechanism by which oxidative damage can 
be responsible for both promoter CpG island specific hypermethylation and global 




 DNMT1 becomes more tightly bound to chromatin after oxidative damage. 
 Oxidative damage induces formation of a complex containing DNMT1, 
DNMT3B and PRC4. 
 DNMT-PRC4 enrichment at CpG islands may explain aberrant gene silencing in 
cancer. 
 Promoters enriched for these proteins have histone mark and DNA methylation 
changes  
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2.4 Introduction 
 
Elevated levels of reactive oxygen species (ROS) arising from alterations in cellular 
metabolism and inflammatory responses constitute a key risk state for increased cancer 
susceptibility (Federico et al., 2007). The major forms of oxidative DNA damage are 
nonbulky lesions such as 8-oxo-2’deoxyguanosine (8-oxo-dG) and thymine glycol that 
are repaired predominantly by base excision repair (BER) (Reardon et al., 1997). 
The above DNA repair requires dynamic changes in surrounding chromatin including 
changes in nucleosome positioning and histone modifications. The best characterized 
chromatin alteration in DNA repair is the phosphorylation of the histone variant H2AX 
(γ-H2AX) by DNA damage response protein kinases (Rogakou et al., 1998). This 
modification helps stabilize the interaction of repair factors with the break sites, leading 
to further chromatin alterations. Histone acetylases and deacetylases also localize to sites 
of DNA damage to facilitate repair by increasing access of repair proteins to the break 
site, repressing transcription at sites of damage, restoring the local chromatin 
environment after repair is complete, and turning off the DNA damage response 
(Tamburini and Tyler, 2005). In this regard, (Sirtuin-1) SIRT1 is a NAD+-dependent 
class III histone deacetylase that plays a role in gene silencing in cancer cells (Pruitt et al., 
2006) and has been implicated in DNA damage repair in both yeast and mammalian cells. 
SIRT1 is recruited to sites of DNA damage and interacts with and deacetylates other 
proteins involved in the DNA damage (For review, see (Fan and Luo, 2010)). After DNA 
repair, DNA methylation also needs to be reestablished, possibly by the recruitment of 
the DNA methyltransferases (DNMTs) that catalyze CpG methylation, including 
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DNMT1 which plays a role in methylating newly replicated DNA (Leonhardt et al., 
1992), and DNMT3A and DNMT3B which are mostly responsible for de novo DNA 
methylation (Okano et al., 1999). 
The above epigenetic players have been linked to patterns of cancer-related gene 
transcriptional silencing, in association with promoter CpG island DNA 
hypermethylation. We, and others, have shown that a large fraction of the genes that 
undergo promoter CpG Island DNA hypermethylation in cancer are unmethylated in 
embryonic stem and progenitor cells and held in low/poised states of transcription by 
polycomb group (PcG) proteins (Ohm et al., 2007; Schlesinger et al., 2007; 
Widschwendter et al., 2007). Importantly, SIRT1 has been described as part of a 
transformation specific PcG complex, PRC4, which is found in embryonic and adult stem 
cells and cancer cells (Kuzmichev et al., 2005). In addition to SIRT1, the PRC4 complex 
contains the PcG proteins, Enhancer of Zeste protein-2 (EZH2) which catalyzes the 
trimethylation of lysine 27 of histone H3 and a specific isoform of EED (EED2) that is 
absent from previously identified PRC complexes. SIRT1 has also been shown to interact 
with DNMT1 (Espada et al., 2007).The DNMTs have been linked to PcG proteins in the 
context of epigenetic gene silencing. Both DNMT1 and DNMT3B interact with EZH2, 
which in turn facilitates the binding of the DNMTs to EZH2 target promoters (Vire et al., 
2006). 
In the present study, we investigate epigenetic alterations induced by the ROS, 
hydrogen peroxide (H2O2), and by inflammation in mouse tissue. We examine changes in 
the interaction and chromatin binding of the epigenetic proteins discussed above and the 
functional consequences of these changes. This work attempts to determine a mechanism 
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by which cancer risk states, such as chronic inflammation, can contribute to cancer-
related abnormal gene silencing and shifts in DNA methylation. 
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2.5 Results 
 
2.5.1 DNMT1 and SIRT1 Become Tightly Bound to Chromatin after H2O2 
Treatment 
Previously, we have demonstrated that SIRT1 and DNMT1 are rapidly recruited to an 
induced double strand break in an exogenous promoter CpG island construct (O'Hagan et 
al., 2008). In this regard, SIRT1, similar to other proteins involved in DNA repair, is 
known to become more tightly bound to chromatin after oxidative stress (Oberdoerffer et 
al., 2008). We now find, by examining resistance of the proteins to salt gradient 
extraction, that both SIRT1 and DNMT1 bind more tightly to chromatin in H2O2-treated 
human embryonic carcinoma cells (NCCIT) despite their unchanged whole cell levels. As 
evidence of this tightening, after H2O2 treatment, a portion of SIRT1 is redistributed from 
the cytoplasmic fraction to the soluble nuclear fraction and is present in all higher salt 
fractions (Figure 2.1A). Basally, as has been previously demonstrated, nuclear DNMT1 is 
loosely bound to the chromatin, being extracted by 0.3 and 0.45 M NaCl (Jeong et al., 
2009). However, after H2O2 treatment, DNMT1 is also eluted in salt fractions of 0.6 M, 
1.2 M, and 1.8 M NaCl (Figure 2.1A). HSP90 and LaminB serve as cytoplasmic and 
nuclear controls, respectively, for the extraction.  
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Figure 2.1. DNMT1 and SIRT1 become tightly bound to chromatin after treatment 
with H2O2. 
(A) NCCIT cells were untreated (U) or treated with 1 mM H2O2 for 30 minutes (T). Cell 
pellets were extracted sequentially using cytoplasmic extraction buffer (Cyto), soluble 
nuclear buffer (nuclear unbound), and buffers with increasing NaCl concentration. Whole 
cell lysates were prepared separately (WCE). (B) HCT116 (WT), HCT116 hypomorphic 
DNMT1 (MT1 hypo), and HCT116 DNMT3B KO (3B KO) cells were treated with H2O2 
at the indicated concentrations in mM for 30 minutes and total nuclear protein was 
collected. y-axis is SIRT1 over Actin levels relative to 8 mM treated WT cells. The data 
presented is the mean of three independent experiments +/- SEM. * p < 0.05 by t-test. (C) 
NCCIT cells were infected with non-specific shRNA (NS) or DNMT1 shRNA. After 72 
hours, they were untreated (Unt) or treated with 1 mM H2O2 for 30 minutes (H2O2). Tight 
chromatin is the remaining protein in the chromatin pellet after extraction with 0.45 M 
NaCl buffer. Band densitometry values are displayed as the ratio of DNMT1 knockdown 
over NS knockdown for protein levels in H2O2 treated cells. The data presented is the 
mean of three independent experiments +/- SEM. * p < 0.05 by one-tail t-test. (D) 
NCCIT cells were transiently transfected with empty vector (EV) or c-Myc-tagged 
OGG1 (Myc-OGG1) plasmids for 48 hours followed by 1 mM H2O2 treatment and 
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2.5.2 DNMT1 Functions Upstream of SIRT1 Recruitment to Chromatin Following 
Oxidative Damage 
We next queried the interdependency of the tightening of SIRT1 and DNMT1 to 
chromatin after H2O2 treatment. SIRT1 knockdown or inhibition causes an increase in the 
fraction of DNMT1 tightly bound to chromatin after H2O2 treatment relative to non-
specific shRNA or mock treated cells, respectively (Figure 2.2A-C). To examine these 
dynamics further, we utilized HCT116 cells genetically rendered hypomorphic for 
DNMT1 or fully deleted for DNMT3B (Rhee et al., 2002; Spada et al., 2007). While 
H2O2 treatment recruits SIRT1 to the nucleus in the WT and DNMT3B KO lines, there is 
a significant reduction in nuclear SIRT1 in the DNMT1 hypomorph cells, both by 
biochemical fractionation (Figure 2.1B) and immunofluorescence (Figure 2.2D). 
However, the residual increase in nuclear SIRT1 in DNMT1 hypomorph cells suggests 
that additional DNMT1-independent mechanisms may exist for changes in SIRT1 
localization after H2O2 treatment. Furthermore, shRNA knockdown of DNMT1 in 
NCCIT cells significantly reduces the amount of SIRT1 that becomes tightly bound to 
chromatin after H2O2 treatment to 0.5 fold of control while simultaneously leading to an 
increase in γ-H2AX levels (Figure 2.1C). While these results suggest that tightening of 
DNMT1 and SIRT1 binding to chromatin after H2O2 treatment are dependent on each 
other, DNMT1 appears to be necessary for the increase in binding of SIRT1 to chromatin.  
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Figure 2.2. Modulation of tightening of DNMT1 and SIRT1 binding to chromatin. 
(A) NCCIT cells were infected with non-specific shRNA (NS) or SIRT1 shRNA. 72 
hours after infection cells were treated with 1 mM H2O2 for 30 minutes. Tight chromatin 
is the remaining protein in the chromatin pellet after extraction with 0.45 M NaCl buffer. 
As a positive control for SIRT1 knockdown we demonstrate, following H2O2 treatment, 
reduced phosphorylated NBS1, which is known to be enhanced via SIRT1-mediated 
deacetylation (Yuan et al., 2007). Band densitometry is displayed as the value for H2O2 
treated cells after SIRT1 knockdown divided by the value for H2O2 treated cells after NS 
knockdown. The data presented is the mean of three independent experiments +/- SEM. * 
indicates p-value < 0.05 by one-tail t-test. (B) NCCIT cells were pretreated with EX-527, 
which inhibits the deactylase activity of the enzyme for 32 hours followed by treatment 
with 1 mM H2O2 for 30 minutes (Solomon et al., 2006). Cell pellets were extracted and 
data analyzed as in (A). The data presented is the mean of three independent experiments 
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+/- SEM. * indicates p-value < 0.05 by a one-tail t-test. (C) Nuclear and cytoplasmic 
extracts from a representative tight chromatin extraction as in Figure 2.2, 2.1C, and 2.1D 
were blotted for a nuclear protein (LaminB) and a cytoplasmic protein (GAPDH). (D) 
WT, DNMT1 hypomorph (MT1 hypo), or 3B KO cells were treated with 4 mM H2O2 for 
30 minutes. Cells were preextracted with detergent and then subjected to 
immunofluorescence analysis using antibodies against SIRT1. Nuclei are stained with 
DAPI. White scale bar is 5 mm. (E) NCCIT cells were untreated or treated with 1 mM 
H2O2 or 5 Gy IR and collected 30 minutes post-treatment. Cell pellets were extracted as 
in (A). Whole cell extracts and the tight chromatin fractions were analyzed by 
immunoblotting. (F) NCCIT cells were untreated or treated with 50 J/m2 UV and 
collected 0.5 or 1 hour post-treatment, or treated with 1 mM H2O2 and collected 0.5 hours 
post treatment. Tight chromatin fractions were extracted as in (A).  
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Because ROS induces DNA damage in the form of base damage, single strand breaks, 
and double strand breaks, we next examined other types of DNA damaging agents and 
found that neither ionizing radiation nor ultraviolet light increase the tightness of binding 
of DNMT1 or SIRT1 to chromatin (Figure 2.2E&F). Additionally, inhibition of poly 
(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair of single and 
double strand breaks, or knockdown of key components of NER does not affect DNMT1 
or SIRT1 recruitment to chromatin after H2O2 treatment (data not shown). Interestingly, 
we demonstrate that H2O2 treatment induces a significantly higher level of DNMT1 in the 
tight chromatin fraction in cells over-expressing c-Myc-tagged OGG1, the DNA 
glycosylase responsible for excising 8-oxo-dG during BER, compared to empty vector 
cells (Figure 2.1D). However, OGG1 overexpression does not affect the tightness of 
SIRT1 binding to chromatin possibly because the chromatin-bound levels of this protein 
are saturated after H2O2 treatment and therefore cannot be increased further by more 
DNMT1 recruitment. 
 
2.5.3 DNMTs, SIRT1, and Polycomb Members Interact, as Part of a Large Multi-
Protein Complex(es), after H2O2 Treatment 
Having demonstrated that H2O2 treatment induces a DNMT1-influenced recruitment 
of SIRT1 to chromatin, we now queried whether such treatment might facilitate 
interactions between the two proteins and with other partners. We first observe, using 
DNMT1 co-immunoprecipitations from NCCIT cells after H2O2 exposure, a time-
dependent interaction between endogenous DNMT1 and endogenous SIRT1 30 and 60 
minutes after treatment (Figure 2.3A). We further validate this interaction by expressing a 
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FLAG-tagged full length DNMT1 in the DNMT1 hypomorph HCT116 cell line and 
finding that H2O2 treatment results in the interaction between the tagged DNMT1 protein 
and endogenous SIRT1 (Figure 2.3B). 
We broadened our search for interacting proteins based on the previously mentioned 
association between DNA hypermethylated genes and PcG marks. In this regard, we 
observe that H2O2 treatment increases the interaction of DNMT1 with EZH2 and EED 
(Figure 2.3B). Further evidence for SIRT1 in this complex is demonstrated by 
immunoprecipitated endogenous nuclear SIRT1 pulling down increased levels of 
DNMT1, EZH2, SUZ12 and the PRC4 specific isoform of EED, EED2, after H2O2 
treatment (Figure 2.3C & 2.4). Total cellular levels of the above proteins do not change 
after treatment (Figure 2.1A and data not shown). Initially, our entrée towards 
recognition of these interactions was based upon our previous demonstration that there is 
an acute recruitment of DNMT3B to an induced double strand break which is dependent 
on SIRT1 (O'Hagan et al., 2008). We now find that H2O2 treatment of NCCIT cells 
results in an endogenous interaction between SIRT1 and DNMT3B, as analyzed by 
immunoprecipitation of DNMT3B. This interaction is detectable within five minutes and 
increases up until 30 minutes after treatment (Figure 2.3D). As has been shown 
previously, DNMT3B and DNMT1 also interact (Kim et al., 2002) and this interaction 
does not change with treatment (Figure 2.3D). Our DNMT3B co-immunoprecipitation 
also reveals that the above interactions occur in the context of PRC4 because there is 
strong interaction of DNMT3B with EZH2, SUZ12 and EED2, both before and after 
H2O2 treatment (Figure 2.3D).  
	   30 
 
 
Figure 2.3. Oxidative damage induces the interaction between SIRT1, DNMTs, and 
PcG components. 
(A) NCCIT cells were untreated or treated with 2 mM H2O2 and collected at the indicated 
time points in minutes after addition of H2O2 to the media. Co-immunoprecipitations 
were performed with control IgG or anti-DNMT1 antibodies. (B) HCT116 DNMT1 
hypomorph cells expressing FLAG-DNMT1 were treated with 8 mM H2O2 for 30 
minutes. Co-immunoprecipitations were performed using control IgG or anti-FLAG 
antibodies. # isoform 2 of EED. (C) NCCIT cells were treated with 2 mM H2O2 for 30 
minutes and co-immunoprecipitations were performed using control IgG or anti-SIRT1 
antibodies. # isoform 2 of EED. (D) NCCIT cells were treated as in (A) and co-
immunoprecipitations were performed using control IgG or anti-DNMT3B antibodies. # 
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Figure 2.4. Validation of cytoplasmic and nuclear fractions for co-
immunoprecipitations. 
Nuclear and cytoplasmic extracts from the co-immunoprecipitation in Figure 2.3C were 
blotted for a nuclear protein (LaminB) and a cytoplasmic protein (GAPDH).  
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The triggering of multiple, individual, interactions suggests the H2O2 induced 
generation of a possible mega-complex(es). To examine this hypothesis, we separated 
nuclear protein complexes by size using sucrose gradient centrifugation from untreated 
and H2O2 treated cells. After H2O2 treatment, DNMT1, SIRT1 and DNMT3B and to a 
lesser extent SUZ12, EZH2, and EED proteins all migrate in the gradient in regions of 
higher molecular mass (greater than 650 kDa) than in untreated cells (Figure 2.5A). 
When we perform DNMT3B co-immunoprecipitation on pooled fractions from the 
gradient in untreated cells, the majority of the PcG proteins (EZH2, SUZ12, and EED2) 
and DNMT1 co-immunoprecipitate with DNMT3B in lower molecular weight pools 1 
and 2 (smaller than 650 kDa – left panel - Figure 2.5B). Importantly, after treatment, the 
co-immunoprecipitation between DNMT3B and the PcG members and DNMT1 now 
shifts towards pools 2 and 3 indicating interaction of the proteins in a much larger 
complex(es) (middle panel - Figure 2.5B). After treatment, SIRT1 interacts with 
DNMT3B in the pools 2 and 3 (middle panel - Figure 2.5B), suggesting that all 
DNMT3B interacting members are present in the same size large complex(es) after H2O2 
treatment.  
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Figure 2.5. H2O2 treatment induces the formation of a large complex(es) containing 
DNA methyltransferases, SIRT1, and polycomb group proteins. 
(A) Nuclear extracts from untreated NCCIT cells or cells treated with 2 mM H2O2 for 30 
minutes were added to a 15 to 60% sucrose gradient and fractions were assayed by 
immunoblotting. Fraction numbers and 650 kDa molecular mass standard are across the 
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Fractions from (A) were pooled into 5 groups as indicated at the bottom of (A). Co-
immunoprecipitations for control IgG or anti-DNMT3B (3B) antibodies were performed 
from the pooled fractions. Right panels are inputs from the pooled fractions. # isoform 2 
of EED. (C) HCT116 DNMT1 hypomorph cells expressing FLAG-DNMT1 were 
untreated or treated with 8 mM H2O2 for 30 minutes. Nuclear extracts, sucrose gradients, 
and pooling of fractions were performed as in (A). Co-immunoprecipitations for control 
IgG or anti-FLAG (Fl) antibodies were performed from pooled fractions. Right panels are 
inputs from the pooled fractions. (D) Flag co-immunoprecipitations were performed in 
HCT116 DNMT1 hypomorph cells expressing FLAG-DNMT1 that were either untreated 
(U) or treated with 8 mM H2O2 for 30 minutes (T). After elution with flag peptide (elute) 
a second immunoprecipitation was done using IgG or EZH2 antibodies. # isoform 2 of 
EED.  
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To examine the above complex formation further, we performed similar gradient 
analyses and co-immunoprecipitations of DNMT1 in the DNMT1 hypomorph HCT116 
cell line exogenously expressing FLAG-tagged full length DNMT1. The input protein 
analyses for this co-IP indicate that there is more nuclear DNMT1, SIRT1, and EZH2 in 
the higher molecular weight gradient fractions after H2O2 treatment than before treatment 
(right panel - Figure 2.5C). In untreated cells, the majority of FLAG-DNMT1 is 
immunoprecipitated from lower molecular weight gradient pools 1 and 2 and interacts 
with EZH2 in pools 1, 2, and 3 (left panel – Figure 2.5C). As expected, SIRT1 is not seen 
prior to treatment. After H2O2 treatment, FLAG-DNMT1 is now immunoprecipitated 
more prominently from pool 3 in addition to pools 1 and 2, peak interaction of EZH2 
with FLAG-DNMT1 is now in pool 3, and interaction is seen with SIRT1 in pools 2 and 
3 (middle panel – Figure 2.5C). Thus, as for DNMT3B, DNMT1 interacts with EZH2 and 
SIRT1 as part of a large multi-protein complex(es) after H2O2 treatment. To demonstrate 
that DNMT1, EZH2, and SIRT1 were indeed all bound together in these large complexes 
we performed sequential co-immunoprecipitation in the FLAG-DNMT1 cells. First, we 
immunoprecipitated DNMT1 containing complexes. After eluting these complexes, we 
immunoprecipitated EZH2 interacting proteins. As demonstrated by the SIRT1 band in 
the EZH2 IP lane in the DNMT1 elute from the treated cells, EZH2 that is bound to 
DNMT1 after H2O2 treatment is also bound to SIRT1 (Figure 2.5D). In total, this data 
suggests that oxidative damage induces the formation of a large complex(es) containing 
the DNMTs and PRC4 members. 
 
2.5.4 DNMT1, SIRT1, and EZH2 Form DNA Damage Foci 
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To determine the possible interactions of DNMTs and members of PRC4 directly 
with DNA damage sites, we performed co-immunofluorescence of key interacting 
proteins with γ-H2AX in NCCIT cells. We used a paraformaldehyde fixation method that 
does not visualize DNA replication foci, since DNMT1 is constitutively present at these 
sites in S-phase (Figure 2.6A). After H2O2 treatment, the chromatin bound protein, 
LaminB, does not co-localize with γ-H2AX foci (Figure 2.6B). In contrast, there is an 
increase in total nuclear DNMT1, and in DNMT1 foci (0.3 foci in untreated and 4.1 in 
treated cells– Figure 2.7B), the majority of which co-localize with γ-H2AX (Figure 2.7C). 
The PcG member, EZH2, behaves similarly to DNMT1 (1.8 to 4.0 foci per cell) (Figure 
2.7A-C). SIRT1, also, exhibits occasional larger foci after H2O2 treatment that co-localize 
with γ-H2AX (Figure 2.7A) but the considerable increase in nuclear staining makes 
precise quantitation difficult. Dense and widely distributed nuclear staining of DNMT3B 
before and after treatment did not allow visualization of foci after treatment. Overall, it 
appears that the tight binding of DNMT1 and SIRT1 to chromatin induced by H2O2, and 
the interaction between these two proteins and other PcG components, occurs, at least in 
part, at DNA damage sites. 
 
2.5.5 Oxidative Damage Recruits Members of the H2O2 Induced Silencing Protein 
Complex to Promoter CpG Islands  
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Figure 2.6. DNMT1 foci in late S phase cells. 
(A) NCCIT cells were untreated or treated with 2 mM H2O2 for 30 minutes. Cells were 
preextracted with detergent, fixed with cold methanol and then subjected to 
immunofluorescence analysis using antibodies against PCNA and DNMT1. Nuclei were 
stained with DAPI. White arrows indicate examples of DNMT1 foci that co-stain with 
PCNA. (B) NCCIT cells were treated as in (A). Cells were preextracted with detergent 
and then subjected to immunofluorescence analysis using antibodies against LaminB and 
γ-H2AX. White scale bars are 5 mm.  
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Figure 2.7. DNMT1 and EZH2 form nuclear foci after H2O2 treatment that co-
localize with γ-H2AX. 
(A) NCCIT cells were untreated or treated with 2 mM H2O2 for 30 minutes. 
Immunofluorescence analysis was performed using the indicated antibodies. White 
arrows indicate examples of foci. White scale bar is 5 mm. (B) More than 50 nuclei from 
cells in (A) were scored per antibody in at least two independent experiments. Graphs 
represent the sample mean +/- SEM. Grey and black bars are untreated and H2O2 treated 
cells, respectively. (C) More than 50 nuclei from cells in (A) were scored per antibody in 
at least two independent experiments. Graphs represent the sample mean +/- SEM. Black 
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We next explored the genomic regions to which the oxidative damage-induced 
complexes may localize using the SW480 colon carcinoma cell line, where we have 
observed similar tightening of DNMT1 and SIRT1 to chromatin after H2O2 treatment 
(Figure 2.8A). We first find, utilizing customized ChIP-chip arrays for chromosome 18, 
19, and 21 and histone H3 as a control, damage-induced concurrent shifts for DNMT1, 
DNMT3B, SIRT1 and γ-H2AX after H2O2 treatment (Figure 2.9A & 2.8B). In each case, 
the chromosome regions with enrichment constitute those previously mapped by others 
(Folle et al., 2010) to harbor high gene transcription activity and GC content. This 
enrichment shift is particularly observable for chromosome 21 where the sub-telomeric 
regions of the chromosome harbor most of the gene transcription and GC content (Figure 
2.9A). Importantly, concomitant to the co-enrichments above, there is a notable loss of 
the same silencing proteins from the transcriptionally inactive and GC-poor regions 
(Figure 2.9A). 
For all three chromosomes examined changes in ChIP signals are most prominent 
around the transcription start sites (TSS) of genes (example for DNMT1 signals in Figure 
2.8C). To explore this finding in more depth, we used promoter arrays to examine the co-
localization of the proteins at gene promoters across the genome. In these promoter 
studies we included, one of the key PcG members, EZH2. We also matched the results to 
previously obtained genome wide expression array data (Easwaran et al., 2010). These 
studies not only confirm targeting of all the tested proteins, after damage, to 
transcriptionally active GC-rich promoter regions, but also extend our findings in key 
ways.  
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Figure 2.8. The silencing complex is targeted to regions of high transcription and 
GC content near TSSs. 
(A) SW480 cells were either untreated or treated with 8 mM H2O2 for 30 minutes. Cell 
pellets were extracted sequentially with cytoplasmic buffer, soluble nuclear buffer, and 
0.45 M NaCl buffer. Tight chromatin fraction is the remaining protein in the chromatin 
pellet after extraction with the 0.45 M NaCl buffer. Protein levels in each fraction were 
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analyzed by immunoblotting. Actin serves as a loading control. (B) SW480 cells were 
either untreated or treated with 2 mM H2O2 for 30 minutes, followed by ChIP for γ-
H2AX, DNMT1, SIRT1, DNMT3B, or H3. Samples were hybridized to the 1M Agilent 
customized whole chromosome ChIP-chip array of chromosome 18, 19, and 21. 
Differences in log2 ratios of IP signals over input signals between treated and untreated 
samples were plotted along chromosome 19 and 18 for the respective antibodies. Red line 
represents the zero (no change) line. Signals above the red line represent gains of 
corresponding marker. Signals below the red line represent losses of corresponding 
marker. (C) Box plots were created by binning probes from chromosome 18, 19, and 21 
on the 1M Agilent array described in (B) according to the distances to their 
corresponding TSSs. y-axis depicts the differences in log2 ratios of IP signals over input 
signals between the treated DNMT1 ChIP sample and the untreated sample. x-axis 
indicates the relative distances of each set of probes to their corresponding TSSs (units 
are in 10 kb for the upper panel and 1 kb for the lower panel). In the upper panel, the 
region from 50 kb upstream to 1000 kb downstream of the TSS is presented in 10 kb 
increments. In the lower panel, the region from 10 kb upstream to 10 kb downstream of 
the TSS is more tightly examined, with probes grouped in 200 bp increments. (D) SW480 
cells were either untreated or treated with 2 mM H2O2 for 30 minutes, followed by ChIP 
for IgG, γ-H2AX, DNMT1, SIRT1, or DNMT3B. The y-axis is the ratio of the IP 
quantitative PCR values over input values between treated and untreated samples. The 
data presented is the mean of three independent experiments +/- SEM. * p < 0.05 and # p 
< 0.1 by one-sided t-test. (E) (F) Box plots for basal expression level of corresponding 
groups of genes analyzed in Figure 2.9C and 5E. y-axis depicts the log2 expression levels. 
In (E), dark green represents the group of CpG island genes, and light green represents 
the group of non-CpG island genes. In (F), red represents the group of CpG island genes 
with high expression, and pink represents the group of non-CpG island genes with high 
expression. Low expression genes for CpG island and non-CpG island genes are 
represented by box plots as indicated on the x-axis. (G) Plots of ChIP-chip signals for γ-
H2AX (green), DNMT1 (red), SIRT1 (blue), DNMT3B (orange), and EZH2 (purple) in 
treated samples over untreated samples for individual genes. y-axis depicts the 
differences in log2 ratios of IP signals over input signals between treated and untreated 
samples. Black dash line represents the no change line. Black vertical bars indicate GC 
percent, ranging from 30% to 100%. Blue lines-boxes represent the position and 
construction of genes, with the boxes indicating the position of exons, lines indicating the 
position of introns, and arrow indicating the direction of transcription. The names of 
genes are indicated at the bottom of the plots.  
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Figure 2.9. Oxidative damage induces recruitment of silencing proteins to the 
promoters of actively transcribed genes and/or high GC content regions. 
(A) SW480 cells were either untreated or treated with 2 mM H2O2 for 30 minutes, 
followed by ChIP-Chip using the whole chromosome array of chromosomes 18, 19, and 
21. Differences in log2 ratios of IP signals over input signals between treated and 
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untreated samples were plotted along chromosome 21. Red line represents the zero (no 
change) line. Signals above and below the red line represent gain and loss, respectively, 
of corresponding marker. (B) Venn diagram for ChIP enriched genes for each antibody in 
treated over untreated samples. SW480 cells were either untreated or treated with 2 mM 
H2O2 for 30 minutes. ChIP samples were hybridized to the 244K promoter array. (C) For 
box plots, the y-axis depicts the differences in log2 ratios of IP signals over input signals 
between treated and untreated samples. For the left panel, red and blue represent the top 
1000 genes with high and low expression, respectively, from expression array data. In the 
right panel, dark and light green represent groups of CpG island and non-CpG island 
genes, respectively. * p < 2×10-10 by two-tail t-test. (D) Plots of ChIP-chip signals in 
treated over untreated samples for individual genes. y-axis is the same as in (C). Black 
dash line represents the no change line. Black vertical bars indicate GC content, ranging 
from 30% to 100%. Blue lines-boxes represent the position and construction of genes, 
with the boxes indicating the position of exons, lines indicating the position of introns, 
and arrow indicating the direction of transcription. Green boxes represent the position of 
CpG islands. The names of genes are indicated at the bottom of the plots. (E) Values 
were plotted as in (C). In the left panel, red and blue represent the top 100 CpG island 
genes with high and low expression, respectively. In the middle panel, pink and light blue 
represent the top 100 non-CpG island genes with high and low expression, respectively. 
In the right panel, blue and light blue represent the top 100 CpG island and non-CpG 
island genes, respectively, with similar levels of low expression. Red dash line represents 
the no change line.  
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First, DNMT1, DNMT3B, SIRT1, EZH2 and γ-H2AX enrichment that is lost from 
transcriptionally poor and low GC-content regions is translocalized to the promoters of 
genes that contain CpG islands and are highly expressed, with a high degree of overlap of 
enrichment between the different proteins (Figure 2.9B-E). The direct targeting to 
promoter CpG islands can be appreciated for example genes, MYC, ACTB, RPL13, and 
RPL10A (Figure 2.9D-left panel). The loss of enrichment for low expression, non-CpG 
island promoter genes is well appreciated for the example genes, HBB, HBD, LAMB4, 
IL8, and MYH1 (Figure 2.9D-right panel). These genomic analyses were confirmed by 
local ChIP and quantitative PCR (Figure 2.8D). 
Second, transcriptional activity is associated with targeting of the members of the 
complex separately from the presence of CpG islands (Figure 2.9E & 2.8E-F). We find 
that high expression genes gain more enrichment than low expression genes in groups of 
genes both with and without CpG islands (Figure 2.9E, left and middle panels). However, 
the presence of CpG islands is still important as targeting is increased in CpG island 
versus non-CpG island genes with similar low basal expression (Figure 2.9E, right panel 
& Figure 2.8F). Further scrutiny of the pattern of translocalization revealed that the 
position of peaks also correlates with areas of high GC content, including but not limited 
to CpG islands (Figure 2.9D [note gene ACTB] & Figure 2.8G), indicating that GC 
content, in addition to the presence of CpG islands, is a contributing factor to targeting. 
Altogether, this data suggests that members of the complex undergo H2O2-induced 
enrichment at gene promoters with high expression and/or high GC-content, including 
those with CpG islands. 
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2.5.6 Functional Consequences of Enrichment of Members of the Oxidative 
Damage-Induced Complex. 
The fact that oxidative damage-induces proteins involved in gene silencing to form a 
complex and be enriched at CpG island-containing promoters, suggests a potential 
functional role of this complex in transcriptional changes accompanying DNA damage 
and/or cancer-specific, abnormal gene silencing. Examination of changes in histone 
marks, transcription, and DNA methylation supports this hypothesis. 
We first examined histone modifications at CpG island-containing gene promoters 
most targeted by members of the complexes. Using genome-wide promoter arrays and 
histone H3 to normalize for nucleosome positions, we observed, as expected, marked 
relative enrichment for the active transcription marks, 3MeK4H3 and AcK16H4, and low 
amounts of the PcG repressive mark, 3MeK27H3, at the promoter of high expression 
genes in untreated cells (Figure 2.10A). After treatment, there is reduction in the active 
marks 3MeK4H3 and AcK16H4, the later is consistent with the deacetylation activity of 
SIRT1, and enrichment of the H3K27me3 mark, which can be catalyzed by the PcG 
component EZH2 (Figure 2.11A). These global changes are verified by examining 
patterns at the CpG island-containing promoters of genes, including, MYC, ACTB, SFRP4, 
MLH1, SFRP5, and TIMP3 (Figure 2.11B) and by local ChIP studies (Figure 2.10B). We 
see similar changes, although with less magnitude, for high expression non-CpG island 
genes (Figure 2.10C left panel). Interestingly, there appears to be a slight gain in 
3MeK4H3 and loss of 3MeK27H3 (Figure 2.10C, right panel) at low expression non-
CpG island gene promoters where there is relative decrease in the complex constituents 
(Figure 2.9E, right panel).  
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Figure 2.10. Histone mark changes after H2O2 treatment occur preferentially at 
promoters of highly expressed and CpG island containing genes. 
(A) Box plots are constructed using the ChIP enrichment for probes within the range of 
2000 bp upstream and 2000 bp downstream relative to corresponding TSSs. y-axis 
depicts the log2 ratios of IP signals over H3 signals. (B) SW480 cells were either 
untreated or treated with 2 mM H2O2 for 30 minutes, followed by ChIP for IgG, H3, 8-
oxoguanine (8-oxoG), 3meK27H3, AcK16H4, or 3meK4H3. The y-axis is the ratio of the 
IP quantitative PCR values over H3 values between treated and untreated samples. The 
	   47 
data presented is the mean of three independent experiments +/- SEM. * p < 0.05 by one-
sided t-test. (C) y-axis depicts the differences in log2 ratios of IP signals over H3 signals 
between treated samples and untreated samples. In the left panel, pink represents the top 
100 non-CpG island genes with high expression, and light blue represents the top 100 
non-CpG island genes with low expression. In the right panel, blue represents the top 100 
CpG island genes with low expression, and light blue represents the top 100 non-CpG 
island genes with similar level of low expression. Red dash line represents the no change 
line. * indicates a p-value of less than 2×10-10 for the corresponding antibody when 
performing a two-tail t-test for the two groups. (D) SW480 cells were either untreated or 
treated with 2 mM H2O2 for 30 minutes, followed by ChIP for DNMT1. Samples were 
hybridized to the Agilent promoter 244K ChIP-chip array. ChIP-chip signals were 
compared between 293 unmethylated genes in SW480 (grey) and 269 methylated genes 
in SW480 (black) that commonly undergo cancer specific DNA methylation. Plots were 
generated by binning probes for the two groups of genes according to the distances to 
their corresponding TSSs in 200 bp increments. The median value for each bin is then 
graphed for each group of genes. y-axis depicts the differences in log2 ratios of IP signals 
over input signals between the treated and the untreated sample. x-axis indicates the 
relative distances of each set of probes to their corresponding TSSs. The difference 
between the two plots is statistically significant between -800 kb to +2000 kb of the TSS 
(except for 1000 to 1200 kb) using two-sided Wilcoxin rank sum tests with p-values of < 
0.05.  
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Figure 2.11. Gene promoters with oxidative damage-induced enrichment of the 
members of the silencing complex have reduced levels of nascent transcription 
and/or increased CpG methylation. 
(A) ChIP samples were hybridized to the 1M promoter array. Plots are of ChIP-chip 
signals from SW480 cells treated with 2 mM H2O2 for 30 minutes over untreated samples. 
Box plots are constructed as in Figure 2.9C except ChIP over input signals are 
normalized to H3. Red and blue represent the top 100 CpG island genes with high and 
low expression, respectively. * p< 2×10-10 by two-tail t-test. (B) Plots are constructed as 
in Figure 2.9D with ChIP signals normalized to H3. (C) SW480 cells were either 
untreated or treated with 2 mM H2O2 for 30 minutes and the nascent RNA was labeled 
concurrently. Quantitative RTPCR data are presented as the mean of the log 2 ratio of the 
treated over the untreated values for three independent biological replicates +/- SEM. * p 
< 0.05 by one-sided t-test. (D) Plots are constructed as in Figure 2.9D. (E) Bisulfite 
sequencing was performed on DNA from SW480 cells that were untreated or treated with 
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biological replicates with at least eight clones per experiment. Circles are the individual 
clones. Black horizontal lines are the mean for all clones with the vertical line 
representing the standard error. p-values by one-sided Welch’s t-test for MLH1, SFRP5, 
and SFRP4 are 0.014, 0.012, and 0.005, respectively. The gradient bar at the bottom 
depicts the relative log 2 basal expression levels, by expression array, which are 11.13, 
6.82, and 6.40 for MLH1, SFRP5, and SFRP4, respectively.  
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Second, the change in 3MeK4H3 levels suggests that enrichment of members of the 
complex may also rapidly induce repressive transcriptional changes mainly in CpG 
island-containing genes with significant basal expression. Indeed, the CpG island-
containing genes, MYC, ACTB, TIMP3, and MLH1, all have reduced nascent transcription 
levels within 30 minutes after treatment (Figure 2.11C). In contrast, the non-CpG island-
containing genes, NANOG, HBD, and IL8, either gain or have no change in their nascent 
transcription levels suggesting that the reduction in transcription for high expression 
genes is not solely due to a global DNA damage-induced decrease in transcription 
(Figure 2.11C). 
Third, we find important correlates for genes that develop cancer-specific, abnormal, 
CpG island DNA hypermethylation. Genes with a high frequency for this change in colon 
cancer that are unmethylated or hypermethylated in SW480 cells, have damage-induced 
enrichment of the silencing proteins (Figure 2.11D & Figure 2.10D). 
Fourth, we examined DNA methylation by bisulfite sequencing for representative 
genes. We did not observe any CpG methylation in the promoter CpG island of the high 
expression gene, MYC, which does not become hypermethylated in cancer (data not 
shown). However, at the short time point examined we find increases in DNA 
methylation for the MLH1, SFRP5, and SFRP4 genes, which are frequently 
hypermethylated in colon cancer but are unmethylated in SW480 cells (Figure 2.11E). 
These three genes are basally expressed to varying degrees in SW480 cells and the level 
of observed increases in DNA methylation are inverse to this expression (Figure 2.11E). 
This finding fits well with emerging data that cancer specific, promoter DNA methylation 
mostly targets genes, which normally have low basal expression (Hahn et al., 2008). This 
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data suggests that localization of members of the complex to gene promoters has 
functional consequences, including histone mark changes, reduction in nascent 
transcription, and/or increases in DNA methylation. 
 
2.5.7 Inflammation Induced Changes in EZH2, SIRT1, and DNMT1 in a Mouse 
Model of Colitis. 
To examine whether our in vitro findings are applicable to the cancer risk state of 
inflammation, we studied an in vivo model of colitis in which infection with the human 
commensal enterotoxigenic Bacteroides fragilis (ETBF) induces inflammation and 
tumorigenesis primarily in the distal colons of Multiple intestinal neoplasia (Min) mice 
which are heterozygous for loss of Adenomatous polyposis coli (Apc) (Rhee et al., 2009; 
Wu et al., 2009). Importantly, in vitro treatment of colon cancer cells with purified B. 
fragilis toxin induces an increase in γ-H2AX and ROS suggesting that this model 
provides an in vivo scenario to assess the endogenous impact of the oxidative damage we 
examined in our in vitro model (Goodwin et al., 2011). First, we examined whether any 
of the players involved in our complex become more tightly bound to chromatin in the 
inflamed distal tissue (Figure 2.12A). Similar levels of Villin, an epithelial marker, 
establish that cells harvested by scraping from ETBF and mock inoculated (sham) mice 
have similar epithelial content, though this method does not obtain pure populations of 
epithelial cells (Figure 2.12B). Using the salt gradient extraction employed in Figure 
2.1A, while we detect no change in DNMT1 (data not shown), we demonstrate that both 
SIRT1 and EZH2 are more tightly bound to chromatin in distal, but not proximal, colon 
epithelial cells from ETBF mice than sham mice two days after inoculation (Figure 2.13A, 
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2.12B & 2.12C). These results suggest the change in binding is due to the specific high 
level of inflammation that occurs during the acute phase of the ETBF model. 
Secondly, we examined whether any of the proteins in our complex interact in the 
inflamed tissue. We performed co-immunoprecipitations using anti-EZH2 antibodies in 
proximal or distal colon epithelial cells from two separate pairs of sham and ETBF mice. 
While in all cases EZH2 co-immunoprecipitates predominantly isoform 1 of EED 
(isoform is determined by comparison to the four isoforms present in mouse embryonic 
carcinoma cells - Figure 2.12D), co-immunoprecipitation of DNMT1 by EZH2 is more 
prominent in the tissue from the distal colon of the ETBF mice (Figure 2.13B & 2.12D) 
suggesting that this interaction is increased by the inflammation in this tissue.  
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Figure 2.12. Mice infected with ETBF have inflammation in their distal colon. 
(A) H&E-stained tissue sections of proximal and distal colon from sham and ETBF-
colonized mice 2 days after inoculation. Histopathology of the distal colon from the 
ETBF-colonized mouse demonstrates mucosal thickening, sub-mucosal edema, and 
inflammatory cell infiltration with rounding and detachment of enterocytes. Arrows 
indicate infiltrating neutrophils. Black scale bars are 50 mm. (B) Salt gradient extractions 
of distal colon epithelial cells from two mice each of Sham and ETBF used in the 
quantification in Figure 2.13A. Mice were mock colonized (Sham) or colonized with 
ETBF. Two days post-inoculation colon epithelial cells were collected by scraping, 
washed with PBS, and extracted sequentially using cytoplasmic extraction buffer (Cyto), 
soluble nuclear buffer (Sol), and buffers with increasing NaCl concentration. Whole cell 
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lysate was prepared separately (WCE). Protein levels in each fraction were analyzed by 
immunoblotting. (C) Salt gradient extractions of proximal colon epithelial cells from the 
second set of Sham and ETBF mice used in (B). (D) Biological replicate of EZH2 co-
immunoprecipitation from Figure 2.13B from a second set of mice. Epithelial cells were 
collected as in (B). Co-immunoprecipitations for control IgG or anti-EZH2 antibodies 
were performed from nuclear extracts where chromatin bound proteins had been released 
by polyamine treatment. Cell extract from mouse embryonic carcinoma cells (EC cells) 
contains all four isoforms of EED and can be used to determine the isoforms present in 
the colon epithelial cells.  
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Figure 2.13. In a mouse model of acute colonic inflammation, members of the 
silencing complex become enriched at promoter CpG islands of low expression 
genes. 
(A) Mice were sham-inoculated (sham) or inoculated with ETBF. Two days post-
inoculation, colon epithelial cells were extracted sequentially using cytoplasmic 
extraction buffer (Cyto), soluble nuclear buffer (Sol), and buffers with increasing NaCl 
concentration. Whole cell lysate was prepared separately (WCE). Blots from one set of 
representative mice are depicted. The value calculated for each fraction is the ratio of that 
fraction over the total of all fractions. The graphs represent the mean values for 3 separate 
mice +/- SEM. * p-value < 0.05 by one-tail t-test. (B) Co-immunoprecipitations for 
control IgG or anti-EZH2 antibodies were performed in nuclear lysates of colon epithelial 
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cells from sham-inoculated mice (S) or ETBF-inoculated mice (E). Blots from one set of 
representative mice are depicted. (C) Using distal colon epithelial cells, ChIP was 
performed for IgG, EZH2, or DNMT1 and analyzed by quantitative PCR. The data 
presented is the mean of ChIP performed in samples from 3 sham and 3 ETBF mice +/- 
SEM. * p < 0.05 by one-sided t-test for the difference between the means. Values below 
the gene names are the expressed sequence tag (EST) counts for mouse intestine from the 
Unigene database.  
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Thirdly, we performed local ChIP for EZH2 and DNMT1 in epithelial cells from the 
distal colon of ETBF and sham mice. Interestingly, unlike the in vitro model, we do not 
see enrichment of EZH2 and DNMT1 at all promoter CpG islands (Figure 2.13C). High 
expression housekeeping genes such as Actb and Gapdh have no change in EZH2 or 
DNMT1 enrichment between the ETBF and sham mice. However, lower expression 
genes, such as Fbn1, Sez6l, Sfrp5, and Sox17, that have higher basal levels of EZH2 than 
the high expression genes, all have more enrichment of EZH2 and DNMT1 at their 
promoter CpG islands in inflamed distal epithelial cells from ETBF mice compared to 
sham mice. Interestingly, three of these genes, Fbn1, Sez6l, and Sox17, have been 
demonstrated to undergo inflammation and tumor-specific DNA methylation in a model 
of intestinal inflammation and all four are methylated in human cancers (Hahn et al., 
2008). These data suggest that, in this model, where changes in ROS are likely less 
dramatic and induced over a longer time frame than for our in vitro model, the 
recruitment of members of the silencing complex is most persistent at promoter CpG 
island-containing genes with lower basal expression. These genes are the most likely to 
be targets of cancer-specific DNA methylation (Hahn et al., 2008).  
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2.6 Discussion 
 
In the present study, we link several proteins involved in transcriptional repression to 
the DNA damage response. We provide evidence for a role for DNMT1 in the response 
of cells to H2O2 treatment. This enzyme becomes more tightly bound to chromatin after 
H2O2 treatment in the context of damage-induced foci that co-localize with γ-H2AX. 
Moreover, DNMT1 appears responsible for the tightening of the PRC4 component, 
SIRT1, to chromatin after H2O2 treatment. SIRT1 has been implicated in the response to 
DNA damage and transcriptional repression in many ways as previously discussed. While 
in inflamed mouse tissue we do not see an increase in binding of DNMT1 to chromatin, 
we see an increase in binding of the PRC4 components, SIRT1 and EZH2. Increases in 
binding of DNMT1 to chromatin may occur at an earlier time point than the one we 
studied, as the in vivo model time point is two days after infection compared to 30 
minutes after treatment for our in vitro model. However, we do implicate DNMT1 in the 
in vivo response to colonic inflammation by demonstrating interaction between EZH2 
and DNMT1 and enrichment of both of these proteins at the CpG islands of low 
expression genes in this inflamed tissue, in a manner consistent with our in vitro results. 
Our observations presented here suggest that tightening of DNMT1 and SIRT1 to 
chromatin after H2O2 treatment is actively associated with DNA damage and/or repair. 
Our evidence by immunofluorescence studies for co-localization of DNMT1, SIRT1, and 
EZH2 to DNA damage-induced foci marked by γ-H2AX suggests targeting to ongoing 
DNA damage. Previously, we have implicated DNMT1 in double strand break repair and 
recently another group has further studied this role for DNMT1 (Ha et al., 2010; O'Hagan 
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et al., 2008). We did not see DNMT1 become more tightly bound to chromatin after IR 
treatment and the observed narrow localization of γ-H2AX signal at the promoter region 
by ChIP-chip after H2O2 exposure is not representative of the typical mega base domain 
enrichment seen after double strand breaks (Rogakou et al., 1999). Thus, our findings 
suggest that, after H2O2 treatment, double strand breaks are not the dominant trigger for 
the dynamics we are reporting. Because levels of OGG1 modulate the tightening of 
DNMT1 binding to chromatin, we suggest that either the specific 8-oxodG base damage 
or the BER pathway that repairs this type of damage is responsible for recruitment of 
member of the silencing complex to chromatin. We propose that the promoter targeted γ-
H2AX is likely marking sites of base damage and this hypothesis is supported by the 
enrichment of 8-oxoguanine at GC-rich promoters after H2O2 treatment. We suggest that 
the enrichment of damage at these areas of high GC content may be because guanine is 
the most easily oxidized of the four deoxyribonucleosides and therefore may be targeted 
by oxidative damage (Steenken, 1997). The co-enrichment of DNMT1, SIRT1, 
DNMT3B, and EZH2 at these sites suggests that these proteins are being localized to 
sites of base damage induced by H2O2 treatment. While in our in vivo model we have not 
assessed whether the enrichment of key complex constituents is also occurring at the sites 
of base damage, it has been demonstrated that purified B. fragilis toxin causes an increase 
in γ-H2AX and ROS in colonic epithelial cells. This data suggests that our in vivo model 
involves a similar induction of oxidative damage as our in vitro model (Goodwin et al., 
2011). 
One of the intriguing implications of our data is the potential role for increased levels 
of cellular ROS that accompany cancer-risk states such as inflammation in the formation 
	   60 
of cancer-specific aberrant patterns of DNA methylation and transcriptional silencing. 
First, as we have noted, cellular transformation has been associated with the presence of 
the PRC4 iso-complex (Kuzmichev et al., 2005) that we now link to DNMTs during 
H2O2 exposure. This complex has altered substrate specificity from the typical PRC2/3 
complexes possibly due to the specific isoform of EED that it contains (EED2) (Kim et 
al., 2007). Since both pre-neoplastic and transformed cells undergo a significant amount 
of endogenous oxidative damage (Federico et al., 2007), the basal PRC4 complex 
previously described in transformed cells may be the same as the complex we describe 
here. Because nuclear SIRT1 levels increase after H2O2 treatment, it is possible that the 
increase in interaction demonstrated between SIRT1 and the other proteins in Figure 2.3 
is due to higher levels of SIRT1, not to an induced interaction per say. However, either 
cause has the same outcome, namely higher levels of the complex. 
Second, our findings suggest one potential mechanism that might help explain a 
conundrum in the abnormalities of DNA methylation in human cancer - namely, why 
cancer cells simultaneously harbor both widespread chromosomal loss of DNA 
methylation and increased DNA methylation in CpG islands of gene promoters (Jones 
and Baylin, 2007). In terms of the losses, we find that enzymes that catalyze DNA 
methylation, DNMT1 and DNMT3B, shift away from non-GC-rich gene and 
chromosome regions. In a similar manner, it has previously been demonstrated in yeast 
and mammalian cells that DNA damage leads to a shift in localization of SIRT1 from 
repressed gene regions to sites of induced DNA damage resulting in transcriptional de-
repression of genes that are basally repressed by SIRT1 (Mills et al., 1999; Oberdoerffer 
et al., 2008). We suggest that when cells are exposed to chronic oxidative damage that is 
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present during all phases of tumorigenesis, the induced shifts in chromosome localization 
that we demonstrate may be associated with losses of DNA methylation observed in 
cancer cells. 
Finally, our observations may also help explain gains in DNA methylation at gene 
promoters in cancer cells. By examining histone mark and transcription changes, we 
demonstrate that enrichment of members of this silencing complex is associated with 
gene silencing. Importantly, however, in cells progressing towards transformation, the 
above translocalization would probably be transient at most genes with high basal 
transcription levels, such as housekeeping genes, and oncogenes, for which silencing 
would be detrimental to tumor cell growth. This hypothesis is supported by the lack of 
EZH2 and DNMT1 enrichment at the promoters of high expression CpG island-
containing genes in the less harsh, longer time-frame, inflammatory in vivo model studied. 
In this regard, active transcription may prevent de novo promoter CpG island methylation 
(Thomson et al., 2010). We demonstrate that genes with a history of frequent, cancer 
specific, CpG island promoter DNA hypermethylation show damage-induced enrichment 
for the members of the complex in cell culture and enrichment of EZH2 and DNMT1 in 
inflamed mouse tissue. In vitro we see an increase in DNA methylation that correlates 
with the low basal expression level of these genes, which harbor PcG complexes in 
embryonic stem and progenitor cells (Ohm et al., 2007; Schlesinger et al., 2007; 
Widschwendter et al., 2007). We hypothesize that such localization of the DNMT-PRC4 
complex and increase in DNA methylation at low expression promoter CpG island-
containing genes might be more persistent over the course of chronic ROS damage 
during tumorigenesis setting up a scenario for the expansion of DNA methylation in the 
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CpG islands involved. Our previous work with a promoter CpG island, double strand 
break DNA damage model, suggests this time-dependent context for the expansion of 
such DNA hypermethylation (O'Hagan et al., 2008).  
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2.7 Experimental Procedures 
 
2.7.1 Antibodies 
 For western blot: DNMT1 (Sigma), SIRT1 (Delta Biolabs, Millipore), γ-H2AX 
(Millipore), EZH2 and Phopho-NBS1 (Cell Signaling), and SUZ12 (Abcam), and 
DNMT3B, Actin, and EED (Sigma). 
 For immunofluorescence: DNMT1, PCNA, and LAMB (Santa Cruz 
Biotechnology), SIRT1 (Millipore), EZH2 (Cell Signaling), γ-H2AX (Millipore). 
Secondary antibodies were FITC anti-Rabbit (Invitrogen) and Alexa Fluor 555 
anti-Mouse (Invitrogen). 
 For co-immunoprecipitation: DNMT3B (described previously (Rhee et al., 
2002)), SIRT1 (Millipore), FLAG (Sigma), Ezh2 (Cell Signaling), Rabbit and 
Mouse IgG (Millipore). 
 For ChIP: DNMT3B (described previously (Rhee et al., 2002)), DNMT1 (Sigma), 
SIRT1 (Millipore), EZH2 (Cell Signaling), γ-H2AX (Millipore), H3 (Abcam), 
3MeK4H3 (Millipore), 3MeK27H3 (Millipore), AcK16H4 (Millipore), and 8-
oxoguanine (Millipore). 
 For ChIP in mouse tissue: EZH2 (Cell Signaling) and DNMT1 (Abcam) 
 
2.7.2 Cell culture, Chemicals, Treatments, and Plasmids. 
NCCIT and SW480 were obtained from American Type Culture Collection and 
maintained at 37oC and 5% CO2 in RPMI-1640 and McCoy's 5a, respectively, 
supplemented with 10% fetal bovine serum. HCT116 WT, DNMT1 hypomorphic and 3B 
	   64 
KO cells were maintained as described previously (Rhee et al., 2002). DNMT1 
hypomorph HCT116 cell line was clonally selected for stable expression of exogenous 
FLAG-tagged full length DNMT1 and maintained in media containing puromycin. For 
H2O2 exposure, 30% H2O2 (Sigma) was diluted in PBS immediately before adding it to 
the medium. Time of treatment is the time after H2O2 is added to the media. c-Myc-Nuc-
hOGG1 (Chatterjee et al., 2006) was kindly provided by D. Sidransky (Addgene plasmid 
18709). For UV exposure, cells were irradiated with 50 J/m2 UV using a Stratagene UV 
crosslinker and incubated at 37 oC for 0.5 or 1 hour. For ionizing radiation, cells were 
exposed to a cesium source at a dose rate of 0.5 Gy/minute for a total of 5 Gy. 
 
2.7.3 Salt Gradient Extraction and Tight Chromatin Fractionation 
Cell pellets were collected 30 minutes after H2O2 exposure, and sequentially washed 
in CEBN buffer (10 mM HEPES [pH 7.8], 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 
10% glycerol, 0.2 % NP-40, 1X protease inhibitor cocktail (Invitrogen), 1X phosphatase 
Inhibitor cocktail and Pefabloc SC AEBSF (Roche Applied Science), N-ethylmaleimide 
(Sigma), CEB buffer (CEBN buffer without NP-40), soluble nuclear buffer (3 mM EDTA, 
0.2 mM EGTA, inhibitors as described above), and salt buffers with increasing NaCl 
concentration (50 mM Tris pH 8.0, 0.05% NP40, NaCl as indicated, inhibitors as 
described above). Tight chromatin fractionation was performed essentially the same as 
the salt gradient except that the only salt wash performed was with 0.45 M NaCl buffer. 
Western blots of the protein extracts were probed with antibodies listed above. Band 
densitometry for western blots was analyzed using ImageJ software. 
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2.7.4 shRNA Knockdown 
Cells were transduced with the indicated lentiviral particles following the 
manufacturer’s protocol (Sigma). 
 
2.7.5 Co-Immunoprecipitation 
Nuclear extraction was performed using CEBN and CEB buffer as described above. 
The total nuclear pellet was resuspended in modified RIPA buffer, sonicated for 12 
pulses, rotated at 4oC for 30 minutes with 30 mM spermine and 10 mM spermidine to 
release chromatin bound proteins, sonicated for 10 pulses, and cleared by high-speed 
centrifugation (20 min, 20,000 x g, 4oC). Nuclear lysates were rotated with antibody 
overnight at 4oC. Rabbit Trueblot agarose beads (DNMT3B and SIRT1 co-IPs - 
eBioScience) or Protein A/G-agarose beads (DNMT1 co-IP – SantaCruz BioTechnology) 
were added and the samples were rotated for 3 H at 4oC. The beads were washed six 
times with TNE + buffer (50 mM Tris pH7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 
0.5% TritonX-100, 50 mM NaF, all inhibitors listed above) for 10 minutes at 4oC. For the 
sequential co-immunoprecipitation, nuclear lysates prepared as above were incubated 
overnight with FLAG-agarose (Sigma). Complexes were eluted off the beads with FLAG 
peptide. IPs were then performed from the elutes using anti-EZH2 antibodies. 
 
2.7.6 Sucrose Gradient 
Nuclear extracts prepared as for co-immunoprecipitation were applied to a 15-60% 
(w/v) sucrose gradient, and centrifuged in a SW41 rotor for 20 hours at 40,000 rpm at 
4oC. Equivalent volumes from each odd fraction were separated by SDS-PAGE and 
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analyzed by immunoblot. The remaining fractions were pooled as indicated. Buffer was 
exchanged to modified RIPA using PD-10 columns (GE Healthcare). Co-
immunoprecipitations were performed from each pool as in the section above. 
 
2.7.7 Immunofluorescence 
Cells grown on coverslips were preextracted using 0.5% Triton-X 100 in 10 mM 
HEPES (pH 7.4), 2 mM MgCl2, 100 mM KCl, 1 mM EDTA, fixed in 4% 
paraformaldehyde, permeabilized in PBS + 0.5% Triton-X 100, blocked in PBST (PBS 
with 0.1% Tween-20) containing 1% BSA, and incubated with the antibodies indicated 
above. DAPI was used to stain nuclei. For methanol fixation, cells were fixed in ice cold 
methanol for 20 minutes. 
 
2.7.8 ChIP-chip 
Cells were crosslinked using 1% formaldehyde and 0.5 mM DSG. Nuclear extraction 
was performed using CEBN and CEB, followed by ChIP-chip as previously described 
(McGarvey et al., 2008) using antibodies indicated above. Samples were either 
hybridized to the Agilent 1M custom array for human chromosomes 18, 19 and 21 or the 
human promoter 244K or 1M ChIP-chip arrays from Agilent Technologies. 
 
2.7.9 Local ChIP 
Cells were crosslinked using 1% formaldehyde. Nuclear extraction was performed 
using CEBN and CEB buffers, followed by ChIP as in (Ohm et al., 2007) using 
antibodies listed above and primers indicated below. 
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  Forward Primer Reverse Primer 
ChIP 
MYC GCCCTTTCCCCAGCCTTAGC AACCGCATCCTTGTCCTGTGAGTA 
ACTB CTCCCTCCTCCTCTTCCTCA TCGAGCCATAAAAGGCAACTT 
NANOG TTGTTGCTGGGTTTGTCTTCAGGTT CGTCTACCAGTCTCACCAAGGCC 
Actb AGCTTCTTTGCAGCTCCTTCGTTG CCATGGTGTCCGTTCTGAGTGAT 
Gapdh CCTGGCACTGCACAAGAAGA CCACCATCCGGGTTCCTATA 
Sfrp5 AAAGACTCAGGGTTCCTCCCAGGT TTCGCCGTTCCCTAGCCAATCT 
Sox17 AAATACGTGCCTCAGAGTCTGCCT TGAAAGGTGCCAATCGACCGCAT 
Fbn1 GGACTGCCTACACGGTCTTAATG TGGCCATGACCCGGTATG 
Sez6l AGATCCCTCTGCCTGGATCCCATT AGAGAGATGGACAGAAGGCTCCAA 
    
RT-PCR 
MYC GTCAAGAGGCGAACACACAA GGCCTTTTCATTGTTTTCCA 
ACTB GAAGCCGGCCTTGCACAT AGCACAGAGCCTCGCCTTT 
TIMP3 GGCGGCAGCAGCGGCAATGAC TACCAGCTTCTTCCCCACCACCTT 
MLH1 GAATGCGCTATGTTCTATTCCATCC ATAGATCAGGCAGGTTAGCAAGCTG 
NANOG GCAGAAGGCCTCAGCACCTA AGGTTCCCAGTCGGGTTCA 
IL8 ACCACCGGAAGGAACCATCTCA AGCACTCCTTGGCAAAACTGCAC 
HBD TGACAAGCTGCACGTGGATCC GGTGAATTCCTTGCCAAAGTTGCG 
    
Bisulfite 
Sequencing 








2.7.10 Nascent Transcription 
Nascent transcription assays were performed using the Click-iT Nascent RNA 
Capture Kit (Invitrogen). Cells were labeled with ethynyl uridine for 30 minutes 
concurrently with the H2O2 treatment if indicated. 
 
2.7.11 Bisulfite Sequencing 
Bisulfite treatment was performed with the EZ DNA Methylation Kit (Zymo). 
Bisulfite sequencing was performed as previously described (McGarvey et al., 2007). 
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2.7.12 Mice 
C57BL/6J mice were handled and inoculated as in (Rhee et al., 2009). Distal and 
proximal epithelium was collected by scraping the mucosal surface of the dissected colon, 
washed three times in PBS, and then subjected to the indicated protocol. Such scraping 
has been shown by others to be an effective method to obtain samples of intestinal 
epithelial cells (Ortega-Cava et al., 2006). ChIP from this tissue was performed using the 
Magna ChIP™ G Tissue Kit (Millipore). All mouse protocols were approved by the 
Johns Hopkins University Animal Care and Use Committee in accordance with the 
Association for Assessment and Accreditation of Laboratory Animal Care International. 
 
2.7.13 Statistical Analysis 
All western blot, immunofluorescence, and local ChIP data are presented as the mean 
+/- standard error (SEM). These data are evaluated by one-tail t-test and considered 
statistically significant with a p-value < 0.05. 
ChIP-Chip data were analyzed utilizing the limma and Ringo packages from 
Bioconductor (Smyth and Speed, 2003; Toedling et al., 2007). ChIP-chip median raw 
values are normalized through Tukey-biweight scaling procedure and smoothed using an 
800 bp sliding window requiring a minimum of 3 probes in the window. ChIP enriched 
regions are identified as regions with three or more significant probes in row assuming a 
nonparametric symmetric Null distribution. Box plots are constructed using the ChIP 
enrichment for probes within the range of 2000 bp upstream and 2000 bp downstream 
relative to corresponding TSSs. Data were tested using two-tail t-test. 
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Normalized basal expression array data were obtained from a previous study 
(Easwaran et al., 2010). Genes with log2 expression levels of greater than 9 or less than 7 
are identified as high or low expression genes, respectively. Human transcriptome data 
were adapted from (Folle et al., 2010). Genomic GC content and CpG island information 
was extracted from the UCSC genome browser. CpG islands are defined as regions 
having a GC content of 50% or greater, being longer than 300 bp, and having an 
observed/expected CG ratio greater than 0.6.  
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2.8 Accession Numbers 
 
Microarray data sets were deposited in the National Center for Biotechnology 
Information's Gene Expression Omnibus (GEO) database 
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3.1 Abstract 
 
The DNA demethylating agent 5-aza-cytidine (5-Aza-CR) shows therapeutic promise 
for advanced, non-small cell lung carcinoma. To help understand this, we match genome-
wide DNA methylation and gene expression responses to 5-Aza-CR in cell lines with 
basal levels of these parameters in the Cancer Genome Atlas (TCGA) project. The 
response signature for the most robust cell line anti-tumor response clusters a small group 
of TCGA lung squamous tumors, and couples low expression and DNA 
hypermethylation of RASSF1 with expression changes, suggesting high cell cycle entry 
and stem cell pathway activity and low apoptotic capacity. A second response signature, 
clusters larger groups of TCGA tumors with downregulation of interferon regulated 
immune responses and the immune tolerance ligand PD-L1. We, thus, suggest a method 
for deriving predictive biomarkers for those NSCLC patients responding robustly to 
epigenetic therapy alone, and a larger group for which early clinical data suggest such 
therapy sensitizes to targeting of immune tolerance.  
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3.2 Statement of Significance 
 
A pre-clinical, genomics based, approach explores promising responses of patients 
with non-small cell lung cancer to therapy employing the DNA de-methylating agent 5-
AZA-cytidine (5-Aza-CR). Cell line genomic data for responses to 5-Aza-CR are 
matched to primary tumor data in the Cancer Genome Atlas (TCGA) project. Signatures 
are derived with relevance to patients responding to the therapy alone, and those 
responding subsequently to therapy disrupting immune tolerance.  
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3.3 Introduction 
 
Innovative strategies are desperately needed to treat the world’s most common cause 
of cancer death, non-small cell lung cancer (NSCLC) (Siegel et al., 2013; Youlden et al., 
2008). Only 15-20% of lung adenocarcinomas (LUAD) harbor genetic abnormalities that 
yield high frequency responses when targeted and are generally followed by acquired 
therapeutic resistance (Shepherd et al., 2005; Vadakara and Borghaei, 2012). In the 
current study, we take a novel genomics based approach to suggest how targeting 
epigenetic abnormalities, associated with frequent gains in gene promoter DNA 
methylation (Baylin, 2011; Jones and Baylin, 2007), may help fill the void for efficacious 
treatments to manage advanced NSCLC. The use of low doses of the DNA demethylating 
agents, 5-aza-cytidine (5-Aza-CR) and 5-aza-deoxycytidine (DAC), is the standard of 
care for patients with certain hematologic neoplasms (Issa and Kantarjian, 2005; 
Silverman and Mufti, 2005). Our recent laboratory studies reveal that transient exposure 
of solid tumor cells to low doses of these agents can lead to a reprogramming response 
which affects populations of tumor self-renewing cells and can blunt their tumorigenicity 
(Tsai et al., 2012). Thus, 5-Aza-CR and DAC might well be useful therapeutic agents for 
the most common cancers. Indeed, our recent clinical trial with low dose 5-Aza-CR, plus 
the histone deacetylase inhibitor (HDACi), Entinostat, shows true therapeutic promise 
(Juergens et al., 2011) in patients with heavily pre-treated NSCLC of both squamous cell 
(LUSC) and adenocarcinoma (LUAD) histologies. About 3% of patients experience 
major RECIST criteria responses which are remarkably durable (Juergens et al., 2011). 
Interestingly, approximately 20% of NSCLC patients receiving epigenetic therapy had 
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robust clinical responses to their immediately subsequent therapy. If continued, this 
would be a very high rate of benefit for the advanced stage NSCLC in the setting of 
resistance to multiple previous therapies. 
 The subsequent therapy responses, which have continued to show durability (Figure 
3.1) included standard cytotoxic drugs (Juergens et al., 2011), and, and as will be 
discussed later, a new form of immunotherapy targeting the PD1 immune tolerance 
checkpoint. While additional clinical trials are needed to validate each of these promising 
observations, and are now starting, these trials will benefit greatly from insights into 
potential mechanisms underlying responses. Biomarker strategies to identify the best 
candidate patients for response to epigenetic therapy alone and those who will receive 
maximum benefit from subsequent therapies are critical. To begin acquiring such data we 
have now employed the laboratory model (Tsai et al., 2012) mentioned above with 
multiple cell lines of NSCLC to explore how low-dose 5-Aza-CR may work for these 
cancers. We first studied the phenotypic responses to the drug matched with timed 
genomic analyses after drug withdrawal. We then explored the implications of all the data 
obtained to primary NSCLC by extrapolating relevant gene expression events and DNA 
methylation changes to basal DNA methylation and gene expression signatures for 
hundreds of primary LUSC and LUAD samples (Hammerman et al., 2012) in The Cancer 
Genome Atlas project (TCGA). The results suggest a genomic strategy for developing 
drugs, which target epigenetic abnormalities in cancer. Most specifically, they show 
potential signatures for groups of NSCLC in TCGA involving DNA hypermethylation 
linked to stem cell, cell cycle, apoptosis, and immune evasion pathways. Our findings 
suggest key potential mechanisms that may underlie clinical efficacy of 5-AZA-CR for 
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NSCLC and suggest strategies for biomarker identification to optimize the use of this and 
related drugs for this deadly tumor type.  
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Figure 3.1. Waterfall plot of response to immediate subsequent therapy after 
progression on epigenetic therapy. 
The best change in defined target lesions, as assessed by RECIST criteria scan 
interpretation, to subsequent systemic anti-cancer treatment following epigenetic therapy 
is shown. The upward red bars indicate increases in tumor size that constitute disease 
progression, the light blue bars constitute stable disease, and the green downward bars 
represent tumor shrinkage qualified to be RECIST criteria response. Green, partial 
response (PR); blue, stable disease (SD); red, progressive disease (PD). The black text at 
the bars specifies the type of subsequent therapy the patient received with the bold text 
showing those who received immune checkpoint immunotherapy. * Indicates a patient 
who received two rounds of epigenetic therapy. This patient received anti-PD-L1 












































































































































































































































































SD              = 43%
PD              = 28%
 
	   78 
3.4 Results 
 
We initiated studies using an ex vivo model in which cells are transiently exposed to 
500 nM 5-AZA-CR. The drug is then withdrawn and the consequences for tumorigenicity 
are mapped in untreated, immuno-incompetent mice. In turn, prior to explanation, cells 
are studied for timed, drug-induced, genome-wide changes in DNA methylation and gene 
expression. We performed such studies on 8 established cell lines of NSCLC, and then 
explore the implications for primary NSCLC querying how the leading changes map for 
genome wide patterns of DNA methylation and RNA-seq gene expression analyses in 
hundreds of tumor samples in TCGA. 
For the 8 NSCLC lines, 4 of the 8 lines showed no anti-tumor response, another 2 
showed only modest effects, while 2 had extended latency for tumor appearance (Figure 
3.2). Of those two, LUAD line (H838), stands out from the other 7 lines by responding 
even to 100 nM 5-Aza-CR while the second LUAD line H1299 responds only to 500 nM 
of drug (Figure 3.2). We then used our genomic approach to search for parameters, which 
correlate with anti-tumor effects (Figure 3.3 & 3.4). Two of the lines which showed no 
anti-tumor effects, HCC4006 and HCC827, had little to no drop in overall DNA 
methylation at either the 3-day point of drug administration or 7 days after withdrawal 
(Figure 3.4A). All other lines exhibited an overall drop in DNA methylation of between 
20-40%. The degree of global de-methylation did not correlate with anti-tumor responses 
(Figure 3.4A).  
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Figure 3.2. Xenografted NSCLC cell lines treated in vitro with 5-Aza-CR in 
NOD/SCID mice. 
Eight NSCLC cell lines were exposed in vitro for 72 hr to 100nM and/or 500 nM 5-Aza-
CR per a previously published paradigm. Mice were never treated with drug. Tumor 
volumes are plotted over time. Black lines indicate data for mock treated cells, blue lines 
for 100 nM 5-Aza-CR treated cells, and green lines for 500 nM 5-Aza-CR treated cells.  
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Figure 3.3. 5-Aza-CR alters gene expression of multiple pathways related to the 
RASSF1 tumor suppressor gene in NSCLC and the relationship to primary NSCLC 
samples in TCGA. 
(A) Effects of 5-Aza-CR mediated expression changes at day 10 in key genes from 
RASSF1 related pathways outlined in the text. The Y-axis displays the ratio of expression 
values (log2) of 5-Aza-CR treated vs. mock treated cells for individual genes labeled on 
the X-axis. (B) Heat map for RNA-Seq expression levels (red for lower and green for 
higher expression values) for samples of primary lung cancers for genes shown in panel 
(A). Top bar: red indicates LUAD and orange indicates LUSC with matching adjacent 
normal lung samples labeled in green and blue as indicated (left panel: all tumor and 
normal samples; right panel: LUAD alone). Genes used in the heat map are listed on the 
Y-axis. Bar panels below the main heatmap show the RNA-Seq expression for the genes 
RASSF1 and IRF7 (red for lower and green for higher expression) Below the bar 
indicating expression for each gene are heat maps of DNA methylation levels across the 
promoter region probes. Probe positions relative to transcription start site are shown to 
the right of the heatmap. CpG island probes are labeled in green. Yellow and blue boxes 
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Figure 3.4. 5-Aza-CR alters gene expression in NSCLC for multiple immune-related 
pathways and the degree of change is associated with degree demethylation. 
(A) Top panel: Gene Set Enrichment Analysis (GSEA) showing upregulation of immune 
pathway genes by 5-Aza-CR in 8 NSCLC cell lines 7 or 10 days after drug withdrawal. 
Normalized enrichment scores are plotted as a heat map. Bottom panel: boxplots showing 
different degrees of demethylation in each of the 8 cell lines as measured by the 
difference in beta values between the 5-Aza-CR and mock treated cells. (B) FACS 
analysis showing increased cell surface PD-L1 after 5-Aza-CR treatment at day 10 in 
H838 and H1299. (C) to (J) Effects of 5-Aza-CR mediated expression changes at day 10 
in key genes from the pathways represented in (A). Y-axis displays the ratio of 
expression values (log2) of 5-Aza-CR treated vs. mock treated cells; X-axis displays 
names of individual genes.  
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For our most sensitive cell line, H838, we noted that at the time of cessation of drug 
treatment on day 3 as well as 7 days later, 5 of the top 10 pathways identified for 5-Aza-
CR induced expression changes for genes involved with the ability of the cell to enter and 
progress through the cell cycle (p-value <10-4 to <10-8, data not shown). These pathway 
analyses also linked these changes to up-regulation of RASSF1, one of the most 
frequently hypermethylated tumor suppressor genes in lung cancer and other 
malignancies (Dammann et al., 2000) (Agathanggelou et al., 2001). Indeed, while 5 of 
the 8 lines tested harbor DNA hypermethylation across the promoter region CpG island 
of RASSF1, and have some drug-induced decrease in DNA methylation in the region 
(Figure 3.5), only H838 cells up-regulate the gene transcript (Figure 3.4A). For the above 
genes noted in Metacore, the link to RASSF1 reflects the fact that this tumor suppressor 
has solid molecular relationships to suppression of cell mitosis through down-regulation 
of events in the PLK1, CDK1, Cyclin B, APCCdc20, and FOXM1 pathway control for 
entry and progression through the cell cycle (Amin and Banerjee, 2012; Chow et al., 
2012; Song et al., 2004). Notably, RASSF1 function is also tied to triggering apoptosis 
though enhancement of TRAIL-Death receptor (DR) signaling (Amin and Banerjee, 2012) 
and the conversion of the HIPPO-YAP pathway from oncogenic to anti-tumor effects 
(Pan, 2010). Finally, its loss of function parallels increases in the sonic hedgehog stem 
cell pathway in basal cell carcinomas (Brinkhuizen et al., 2012). Remarkably, and 
virtually uniquely in the H838 cells, there are coordinate changes in expression for genes 
in all of the above pathways. Thus, there are 5-AZA-CR induced decreases in multiple 
genes for entry into and progression through, the cell cycle, many tied to the FOXM1 
pathway, in concert with the RASSF1 transcript increases (Figure 3.3A). These events 
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include 2-fold down-regulation of the key oncogene, E2F1 in H838 cells, while only one 
other cell line, H460 (data not shown), has a marginal decrease. This protein interacts 
with the RB tumor suppressor to increase cell cycle activation (Dimova and Dyson, 2005). 
These cell cycle gene changes were accompanied in H838 cells by 5-Aza-CR induced 
decreases for the pro-survival genes BCL2 and BIRC5 (SURVIVIN) and increases in the 
pro-apoptosis genes TRAIL receptors, TNFRSF10B and TNFRSF10D as well as the 
autophagy genes BIRC2 and BIRC3 (Figure 3.3A and data not shown). Finally, the key 
driver genes for the SHH pathway, SMO, GLI1, and GLI2, were all decreased and there 
was concordant down-regulation of the FYN oncogene and many related members of the 
SRC related protein-tyrosine kinase pathway (Montero et al., 2011), and linked to ITGB4, 
a key integrin related to metastatic lung cancer cell behavior (Yang et al., 2010) (Figure 
3.3A and data not shown).  
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Figure 3.5. Cell line promoter DNA methylation status, assessed as beta value on the 
Y-axis obtained from Illumina Infinium HumanMethylation450 BeadChip. 
Genomic location is labeled on the X-axis with black vertical bristles indicating the 
position of probes. Gene structures are displayed at the bottom. Green box indicates the 
location of CpG island. Red lines indicate data from mock treated cells, and blue lines 
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We next examined how 5-Aza-CR induced gene expression changes unique to H838 
cells might relate to hundreds of primary LUAD and LUSC TCGA samples 
(Hammerman et al., 2012). We examined the promoter CpG island DNA methylation 
status of RASSF1 as analyzed by the identical Infinium 450K used in the above cell 
culture studies, and expression of this gene and other gene changes unique to H838 cells, 
as mapped by RNA-seq, as outlined in Figure 3.3A. Two important signatures emerged 
which clustered tumors from one another and separated them from normal lung samples 
in TCGA. First, a group of tumors (within the yellow box, Figure 3.3B), virtually all 
LUSC, and constituting 36% of the 195 NSCLC samples, have higher basal expression of 
genes for control of cell cycle entry and progression. Second, within this group there is a 
smaller subgroup (blue box, Figure 3.3B, 18% of NSCLC cases) wherein RASSF1 
hypermethylation and lower expression accompany not only higher basal expression of 
the above genes for control of cell cycle entry and progression, but also of key SHH 
activation genes, and of the pro-survival genes SURVIVIN, and, in a smaller group, BCL2. 
In concert, basal levels are decreased for pro-apoptotic genes, especially notable for 
TNFRSF10D (Figure 3.3B). Third, when LUAD is depicted separately (Figure 3.3B, right 
panel) it can be appreciated that there is a group of tumors having some of the basal gene 
patterns for all the pathways as outlined for LUSC, but especially for higher expression 
of all the cell cycle genes. Thus, the above smallest groups of LUSC and LUAD patients 
could relate to patients likely to benefit from 5-Aza-CR alone. Indeed, only a small group 
of patients with advanced NSCLC showed RECIST criteria responses to epigenetic 
therapy alone, but these were extremely durable. Moreover, both groups of LUAD and 
LUSC driven by the cell cycle gene pattern may also relate to patients who subsequently 
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respond to cytotoxic therapies as promising data indicate in the clinical trial (Figure 3.1). 
For example, inhibitors of FOXM1, PLK1, CDK’s, CHEK1, and AURORA kinases are 
all being developed with the goal of re-establishing cell cycle checkpoints to sensitize 
patients to chemotherapies (Campos and Dizon, 2012). 
We followed another lead from the Metacore analysis of gene expression responses to 
5-Aza-CR and which treatment which related to multiple of the cell lines. Multiple 
immune –related pathways were among the top-most altered in response to 5-Aza-CR (p-
value <10-3 to <10-5, data not shown) in virtually all the treated cell lines. These changes 
indicate an up-regulation by 5AZA-CR for a complex tumor immune evasion signature. 
Given the early suggestion in our epigenetic therapy trial that the regimen may provide 
subsequent sensitization to therapy targeting immune tolerance checkpoints, we intensely 
pursued these findings. The Gene Set Enrichment Analysis showed significant up-
regulation of immune-related pathways in a manner roughly correlating to the degree of 
demethylation in response to 5-Aza-CR treatment (Figure 3.4A). 5-Aza-CR has been well 
described by others to up-regulate individual steps in immune pathways including those 
for tolerance-maintaining proteins in lymphocytes, assembly of major histocompatibility 
antigens (MHC or HLA Class I), interferon pathway genes, and cancer-testis and other 
surface antigens (Claus et al., 2005; Fonsatti et al., 2007; Simova et al., 2011). Each of 
these events is required for the immune tolerance pathways targeted by immune 
checkpoint therapy (Pardoll, 2012) and some of these genes have low expression in 
cancers associated with cancer-specific increases in promoter region DNA methylation, 
and increased expression after treatment with DNA demethylating drugs (Kulaeva et al., 
2003; Li and Tainsky, 2011). Importantly, when compared to normal bronchial epithelial 
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cells, NSCLC cells are known to exhibit diminished innate immune responses to viral-
like stimuli, involving intertwined pathways of cell-intrinsic responses to infection and 
inflammation (Li and Tainsky, 2011). Finally, NSCLC commonly express low levels of 
genes for antigen processing and presentation, which are required for recognition by 
tumor-targeting T-cells (Li and Tainsky, 2011). Given all of the above, we extensively 
mined our DNA methylation and gene expression data for how our pre-clinical model of 
low dose 5-Aza-CR might alter immune responses. 
As might be expected, given that our tumor responses are monitored in immuno- 
incompetent mice, the immune pathway responses do not correlate with extent of anti-
tumor response, as do the pathways analyzed in our studies in Figure 3.2 and 3.3. 
However, as shown in schematic form (Figure 3.6), and in GSEA (Figure 3.4A), and in 
examination of individual genes (Figure 3.4C-J), low-dose 5-Aza-CR, at day 10, induces 
an extensive, complex reprogramming of the multiple immune pathways mentioned. A 
first key point is that activation of the JUN/FOS signaling response to cell stress 
(Hernandez et al., 2008; Van der Velden et al., 2012) is central to activation of all of the 
above immune-related pathways (Figure 3.4A & 3.6), and treatment with 5-Aza-CR up-
regulates expression of multiple central member genes including JUN, JUNB, JUND, 
FOS, and key interacting factors BATF, BATF2, and BATF3 (Figure 3I). Members of the 
BATF family are emerging as particularly important transcriptional regulators of immune 
cell differentiation and function (Glasmacher et al., 2012; Logan et al., 2012). Next, there 
is increased expression of a series of genes critical for initial recognition and processing 
of viral RNA and subsequent triggering of interferon pathways (Figure 3.4A, 3.6) 
including STING (TMEM173), IFIH1 and interacting factors IFIT1, IFIT2 and IFIT3, and 
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IFITM1, IFITM2, IFITM3, and IFITM4 and RIG I (DDX58) (Hsu et al., 2012; Ishikawa 
et al., 2009) (Figure 3.4F and data not shown). In parallel, genes for initiation and 
maintenance of the interferon response to viral infection, such as G1P3 (IFI6), are 
concordantly up-regulated (Figure 3.4F) as are many downstream pro-inflammatory 
pathway genes linked to viral defense responses (Cheriyath et al., 2011) including 
multiple interferon, TNF-alpha, and cytokine genes. 
Importantly, we observe multiple clues for how agents like 5-Aza-CR might sensitize 
NSCLC to anti-immune tolerance therapy. One key component of immune tolerance, and 
effective for inhibiting it, is the dependence of both processes on recognition by T-cells 
of surface antigens, both of a general nature, and very specifically of MHC or HLA Class 
I targets (Pardoll, 2012). In terms of the former, as recognized by others (Claus et al., 
2005; Fonsatti et al., 2007; Simova et al., 2011), 5-Aza-CR increases expression of 
multiple cancer testes antigens (Figure 3.4G) including multiple MAGE family genes, 
whose expression has been shown to be suppressed in non-transformed cells via promoter 
hypermethylation (Claus et al., 2005; Fonsatti et al., 2007). Also, 5-Aza-CR up-regulates 
not only transcripts for virtually all HLA Class I antigens but also, concordantly, of a 
series of genes including, beta-2-microglobulin (B2M), TAP1, and the immuno-
proteasome subunits LMP-2 (PMSB9) and LMP-7 (PSMB8) (Figure 3.4D), which encode 
proteins required for endoplasmic reticulum processing, transport, and anchoring of 
MHC-I subunits to the cell surface, and CD58, which helps MHC-I mediate immune cell 
attraction (Challa-Malladi et al., 2011; Procko and Gaudet, 2009; Raghavan et al., 2008). 
Of note, there are mutations of HLA-A in a small percentage of LUSC (Hammerman et al., 
2012) and also of B2M and CD58 in other tumor types (Challa-Malladi et al., 2011). 
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These mutations have all been incriminated as genetic events which can provide 
mechanisms for immune evasion. 
Second, in vivo, 5-Aza-CR administration to tumor-bearing mice has been shown to 
induce antigen processing and presentation genes, particularly when administered with 
CpG TLR9 agonists, and this is largely attributed to interferon-γ production by 
lymphocytes (Simova et al., 2011). While the lymphocyte-specific γ-interferon is not 
ectopically induced in NSCLC lines with 5-Aza-CR treatment, there is robust induction 
of the gene encoding the inducible subunit of the interferon-γ receptor (IFNGR1), but not 
the interferon-β receptor (IFNAR2), as well as of multiple STAT genes, including STAT1, 
the major IFNGR1 signal transducer (Figure 3.4E).  
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Figure 3.6. Schematic of the immune and death related processes that were analyzed 
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Importantly, for the cell studies, 5-Aza-CR treatment influences a key tumor cell 
event, presence of PD-L1 on the cell surface, which is an essential target for therapy to 
inhibit immune tolerance. This is the major immune checkpoint ligand for the interacting 
immune cell receptor, PD-1 (Pardoll, 2012). In the reported anti-PD-L1/PD-1 clinical 
trials (Brahmer et al., 2012; Topalian et al., 2012), in a small subset of the patients 
analyzed, responses did not occur in patients whose tumors did not express cell surface 
PD-L1 (Topalian et al., 2012). 5-Aza-CR increases the PD-L1 much more frequently than 
it does for PD-L2, a second dendritic cell/macrophage ligand for PD-1, or other 
checkpoint ligands such as B7-H3 and B7-H4 (Pardoll, 2012) (Figure 3.4C). Importantly, 
CD80 and CD86, ligands for the immune checkpoint receptor CTLA4, another target in 
immunotherapy strategies (Pardoll, 2012) are not altered (Figure 3.4C). Importantly, PD-
L1 expression in tumor cells can either be driven by cell-intrinsic mechanisms, or in a 
process termed adaptive resistance (Pardoll, 2012), by interferon-γ signaling and 
subsequent activation of STAT transcription factors, which we show earlier to be induced 
by 5-Aza-CR (Figure 3.4E). We have performed FACS analyses for expression of PD-L1 
protein on the surface of two of the NSCLC lines (Figure 3.4B). Consistent with the 
transcript changes, 5-Aza-CR increases this tumor ligand, as compared to mock treatment 
in both instances. We also looked at other selected immune-related proteins HLA Class I, 
B2M, CD58, and B7-H3 for their appearance on the cell surface and found generally 
good correlation with 5-Aza-CR induced transcript increases (Figure 3.7).  
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Figure 3.7. Comparison of Agilent expression array data to flow cytometry for select 
cell surface proteins in H838. 
Clear bars represent the log2 ratio of mean fluorescence intensity of 5-Aza-CR over mock 
treated cells. Hashed bars represent the M-values of expression array (log2[5-Aza-
CR:Mock]). For HLA Class I, the antibody used in flow cytometry does not discriminate 
subtypes of class I molecules. Individual class I molecule subtype transcript data are 
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A final key point to be addressed for all the cell line data above is a potential 
intersection between the immune pathway events and the other pathways which have 
emerged, especially in triggering cell death. These overlaps may be important 
determinants of the anti-tumor responses in our most sensitive cell lines, even in an 
immuno-incompetent mouse, and in patient responses. In this regard, the pro-
inflammatory and viral defense pathways harbor what has been termed “the dual face” of 
pro-inflammatory and viral defense responses for promoting or inhibiting cell death 
and/or tumorigenesis (Dunn et al., 2002; Ishikawa et al., 2009; Sharma and Fitzgerald, 
2010). These death signals are triggered predominantly by increased extent and duration 
of cell challenges, like viral infection, such that involved cells must be eliminated (Dunn 
et al., 2002; Ishikawa et al., 2009; Sharma and Fitzgerald, 2010). Many of the apoptotic 
pathways involved trigger the same down-stream gene expression events shown in Figure 
3.3A and 3.4F, 3.4H. In terms of the specific immune genes with potential for inhibiting 
tumor growth, 5-Aza-CR triggers up-regulation of IFI27, especially in H2170 LUSC 
cells (Figure 3.4F), which encodes a protein triggering apoptosis in late stages of chronic 
viral infection (Cheriyath et al., 2011). Simultaneously, there is down-regulation of the 
anti-apoptotic gene, MAVS (Figure 3.4H), a change that accompanies RIG I signaling in 
response to viral challenge (Sharma and Fitzgerald, 2010; Xu et al., 2010). Downstream 
events in these viral response death signals involve the signature seen in our most 
sensitive H838 cells, as previously discussed, including increases for expression of BIRC 
family, autophagy genes (Yang and Klionsky, 2010) and simultaneous decreases in the 
anti-apoptotic genes BCL2 and BIRC5 (SURVIVIN) (Figure 3.4A & 3.4H). Interestingly, 
the SURVIVIN response is known to be triggered by the viral induction of IRAK3, a gene 
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expression increase unique for the H838 cells. This gene encodes for an IL-1 receptor 
associated kinase (De Carvalho et al., 2012). IRAK3 is silenced in colon cancer cells in 
association with promoter-region DNA hypermethylation and when reactivated by 
demethylation, is associated with BIRC5 down-regulation (De Carvalho et al., 2012). In 
addition, many other apoptosis triggering genes central to inflammation and viral-defense 
(Benedict et al., 2002; Strowig et al., 2012) are altered in our cells including caspases, 
TNF pathway genes, and interleukins. 
To search for potential driving events for all of the immune-related changes induced 
by the transient 5-AZA-CR treatment, we next examined induced promoter de-
methylation and increased gene expression of key upstream transcription factors (TFs) 
(Figure 3.8A). We identified approximately 300 genes with high baseline promoter 
region CpG island methylation, promoter demethylation of 25% or more after treatment, 
and expression increased by log2 0.5 (1.4-fold) or greater after treatment (Figure 3.4A, 
Table 3.1). Nearly 17% of these are in an interferome database 
(http://www.interferome.org), and 52 (19%) are TFs (Bidwell et al., 2012; Samarajiwa et 
al., 2009). The TF, IRF7, has been reported by others to be hypermethylated in cancer 
(Jee et al., 2009; Li and Tainsky, 2011; Lu et al., 2000), as it is in our NSCLC line with 
the lowest basal expression (Figure 3.9). It is up-regulated in response to 5-Aza-CR in 
several cell lines, most prominently in the LUSC cell line H2170 showing a 9-fold 
increase (Figure 3.4J) (Li and Tainsky, 2011). This major upstream activator functions in 
cellular pathways recognizing the virus response element VRE-A to increase 
transcription of genes involved in type 1 IFN signaling (Li and Tainsky, 2011). PScan 
analysis confirms, by presence of these sequences, a significant association of IRF7 
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transcription targets with genes which drive GSEA enrichment scores for the immune 
pathway alterations observed in response to 5-Aza-CR (Table 3.2). The same dynamics 
hold true for PITX1, up-regulated by 5-Aza-CR in our second most anti-tumor responsive 
cell line, H1299 (Figure 3.4J & 3.9), which acts at the distal negative regulatory element 
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Figure 3.8. Genes highly up-regulated in H2170 by 5-Aza-CR are associated with 
IRF7 in NSCLC. 
(A) Left panel: Plot of genes with high baseline DNA-methylation of promoter region 
CpG island probes (Infinium beta values > 0.5) which demethylate by 0.25 or more at 
day 3 and/or day 10 with 5-Aza-CR treatment and which show a gene expression 
increases of 0.5 or more (log2) in NSCLC cell lines (color of dots indicate cell line and 
time point, X-axis indicates differences in beta values between mock treated and 5-Aza-
CR treated cells, Y-axis displays expression values as log2 differences between 5-Aza-CR 
vs. mock treated cells). The red box encompasses genes meeting the described criteria for 
DNA methylation decrease and gene expression increase. Right panel: Selected 
transcription factors meeting the described criteria. The full list of genes up-regulated by 
5-Aza-CR according to the described criteria is listed in (Table 3.1). Two key immune-
related TF genes, IRF7 and PITX1, are highlighted in yellow in the right panel. (B) Heat 
map of genes derived from the LUSC cell line H2170 using RNA-seq data for primary 
LUSC and LUAD samples from the TCGA. The genes are those 4-fold or more up-
regulated in H2170 in response to 5-Aza-CR in coordination with a 9-fold increase in 
IRF7 expression for samples of primary lung cancers (red for lower and green for higher 
expression values). This gene list is highly associated with IRF7 as transcription factor 
targets based on PScan analysis (p = 7.6 e -18, Table 3.2). Top bar: red indicates LUAD 
and orange indicates LUSC. Genes used in the heat map are listed on the Y-axis as well 
as in Table 3.3. (C) Bar panels show the expression spectrum for the indicated genes 
(PD-L1, IRF7, and PITX1) in five quantile intervals (red for lower and green for higher 
expression). Heat maps immediately below each expression spectrum bar panel are 
Infinium DNA methylation data across the promoter region for CpG probes with 
positions relative to transcription start site shown to the right (red for more and green for 
less methylated). CpG island probes are labeled in green. Order of samples in bar panels 
and heat maps is maintained from hierarchical clustering in panel (B).  
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Table 3.1. Complete list of genes that are re-expressed for 0.5-fold or more (log2 
scale), promoter region CpG island hypermethylated in mock treated cell, and 
demethylated for greater than 25% by 5-Aza-CR in the eight NSCLC lines. 
Identified transcription factors are labeled in red. Genes identified by the interferome 
database are underlined. 
 
A549 H1299 H2170 H358 H460 H838 HCC4006 HCC827 
AJAP1 AKAP12 AKAP12 ADAM23 ACTN2 ALDH1A3  UBE2DNL 
AKAP12 ANKK1 BIK CACHD1 AJAP1 C1orf190    ALDH1A3 ANPEP BNIP3 CCK AKAP12 C2orf84    AMPD3 APH1B CD38 COL7A1 AKR1E2 CD248    ANKK1 BIK CLDN23 CRHR1 ALDH1A3 CDK5R1    ANKRD53 C20orf46 COCH CYB5R2 ALPL CPT1C    ANPEP CLIC3 DDX43 DSE APH1B CYP11A1    BIK COL9A3 EIF5A2 ENG AQP5 DNALI1    C5orf58 DNALI1 ELF4 FBXO2 ASPRV1 EFHD1    C9orf140 FAM132A FBXO2 FZD7 BNC1 ELMO3    C9orf4 FERMT3 FERMT3 HIC1 C20orf46 ESRP2    
CCDC144NL FMR1NB FLNC HIST1H2AD C8orf84 FAM50B    CCK FZD7 FMR1NB HIST1H2AE CAND2 FES    CES1 GDF15 FSTL1 HR CAPS GDF15    CHTF18 GPRC5B FTHL17 LIMS2 CCDC144NL HES5    CLDN4 H1F0 GATA3 MEIS2 CCND2 HIST1H2BJ    CLIC3 HIC1 HERC5 MFI2 CD248 HSD17B8    CLIC6 HOXD13 HLA-F MSI1 CD38 ICAM4    COL9A3 ICAM1 HOXC9 PCDHGA7 COL9A3 IFFO1    CREB3L1 ICAM4 HSPA2 PDLIM4 COX7A1 INA    CTCFL ID4 IFFO1 PITX2 CPT1C IRF7    CYB5R2 LOC151534 IGF2BP1 PLEK2 CTCFL IRX5    DDX43 LPIN3 IRF7 PTHLH D4S234E ISG15    DNALI1 LRFN4 IRS1 PTPRS DBNDD2 KLHDC7B    DPEP3 LY6K KLF11 RGMA DDX43 LOC654433    DUSP2 MEST KLHDC7B SDHAP3 DKK3 MAFG    ELL3 MFI2 LOC654433 SGK1 DNAJA4 MEI1    FAM20A PITX1 MARVELD1 SLC16A1 DNALI1 MST1R    FAM83H PLD6 MFI2 TCF15 DPEP3 NEFH    FBLN2 PLLP MT1L TNFRSF25 DZIP1 NES    FBXO2 PP14571 NES TTTY14 EHD3 NTF3    FERMT3 S1PR4 NKAPL UCHL1 ELF4 POMC    FES SLC4A11 PCDHGA3   ELOVL2 PRDX2    FMR1NB SPINT2 PLBD1   F2RL1 PSMB8    FRZB TMEM204 PLEK2   FABP5 REC8    FSTL1 TRIM74 PNLDC1   FAM118A ROBO3    FZD10 TRIP6 PPP1R14A   FAM150B S1PR4    GATA3 TYRO3 REC8   FAM20A SLC15A3    GJB2 VWCE SCIN   FAM3B SOX15    GPRASP1 ZNF239 SLC15A3   FAM50B STAG3    GSTM2   SLC16A5   FBLN2 TDRD12    H19   SOHLH2   FBXO2 TMEM88    HIST1H1B   STOM   FKBP1B TNFRSF25    
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A549 H1299 H2170 H358 H460 H838 HCC4006 HCC827 
HIST1H2AD   TDRD12   FMR1NB VAMP5    HIST1H2AE   TDRD9   FOXF1 VWCE    HIST1H2BG   TSPYL6   FRZB WDR69    HIST1H3D   VWCE   FZD10 ZNF300    HLA-F   ZNF502   GALNT3      HOXA5   ZNF578   GCC1      HPDL      GDF15      HRASLS5      GFRA1      HSPA2      GPC2      ICAM1      GPX7      IFFO1      H19      INPP5D      H1F0      IRF7      HS6ST1      ISG15      HSPA2      ISYNA1      ID4      JAM3      IFFO1      KANK4      INPP5D      LOC654433      IRF6      LRFN4      IRF7      LY6K      IRX5      MAGEB1      ISG15      MEG3      ISYNA1      MEIS2      KIAA1614      MFI2      KLHDC7B      MST1R      KRT7      MX1      L1TD1      MYL9      LAYN      NAV1      LRRK1      NEFH      MAGEB1      NEFM      MEG3      NINL      MEST      NUDT11      MEX3A      PITX2      MFI2      PLBD1      MT1M      PLEK2      MX1      PLLP      MYO5C      POU4F1      NAPRT1      PRSS21      NEFH      RAB31      NINL      RBM46      NKAPL      REC8      PCDHGA2      SEMA6C      PCDHGA3      SIPA1L3      PCSK9      SLC12A8      PDIA2      SLC4A11      PER3      SPOCK2      PLAGL1      ST3GAL2      PLBD1      STAG3      PLEK2      TCF15      PNLDC1      TCF21      PNPLA3      TDRD12      POMC      
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A549 H1299 H2170 H358 H460 H838 HCC4006 HCC827 
TDRD9      PTGER4      TLX2      PTHLH      TMEM204      RASL11B      TMEM220      RFTN1      TNFRSF10C      RGAG4      TNFRSF25      RGMA      TNPO2      RIBC2      TRIM29      RIPK4      TRIM45      RPRM      TRIM74      RUNX3      UBE2DNL      SCRN1      VAMP5      SERP2      VWCE      SFRP1      WDR69      SLC4A4      ZIK1      SLIT2      ZNF578      SOHLH2      ZNF75A      SOX11             SPESP1             SPINT2             SPOCK2             SST             STAG3             STK32B             STOM             TAC1             TCF15             TDRD12             TDRD9             TMEM171             TMEM88             TNFRSF10C             TNFRSF25             TRIM45             TRIM74             TSPYL5             TSPYL6             VWCE             ZNF167             ZNF300             ZNF331             ZNF502      
        ZSCAN18       
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Figure 3.9. Plots (left for IRF7 and right for PITX1) are generated similarly as in 
Figure 3.3B for mock-treated samples in the eight NSCLC cell lines. 
Top panels: bar plots of gene expression levels (log2 intensity). Bottom panels: heat maps 
for corresponding DNA methylation levels (red for more and green for less methylated) 
plotted across the promoter region as in Figure 3.3B with the probe positions from the 
transcription start sites on the Y-axis with the CpG island probes marked in green. 
Samples are ordered by their expression levels (from left to right, low to high), as 






















































































Table 3.2. PSCAN analysis of the association of the transcription factor IRF7 with 
gene lists from Figure 3.4A and 3.8B. 
PSCAN assigns a measure of statistical association for a transcription factor with a given 
gene list. The table reports estimated p-values using the TRANSFAC database of co-
expressed and co-regulated genes when analyzing -450 to +50 base pairs of promoter 
sequences in the defined gene lists. 
IRF7 
4-Fold Upregulated in H2170 7.6 e
-18 
Reactome  Interferon Alpha Beta 4.7 e
-14 
Death Genes 5.7 e
-08 




KEGG RIGI Like Receptor Signaling 1.3 e
-04 
KEGG Toll Like Receptor Signaling 4.5 e
-04 
Reactome IFN Gamma 3.3 e
-03 
Immune Tolerance Regulation 0.042 
KEGG Antigen Processing and Presentation 0.33 
KEGG NFKB 0.40 
Stress Response 0.87 
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Table 3.3. Genes 4-fold or more up-regulated in H2170 at day 10 (7 days post 5-Aza-CR withdrawal). 
Gene symbols are indicated in the first column of each panel, the fold changes of the gene expression levels by 5-Aza-CR at day 10 in 
H2170 are in the second column, availability of RNA-Seq expression data is indicated in column 3, and the chromosomes on which 
the gens reside are indicated in column 4. Only genes that reside on autosomes and have available TCGA RNA-Seq data are used to 


























ADAM8 13.1 Yes 10 HLA-F 4.1 Yes 6 PARP12 5.5 Yes 7
ANKRD1 8.1 Yes 10 IFFO1 4.0 Yes 12 PARP14 4.2 Yes 3
ANXA8L2 6.0 Yes 10 IFI16 7.8 Yes 1 PARP9 7.3 Yes 3
AREG 4.1 Yes 4 IFI27 22.2 Yes 14 PLAT 4.3 Yes 8
ARHGDIB 5.8 Yes 12 IFI44 25.0 Yes 1 PLK2 4.2 Yes 5
B2M * 3.9 Yes 15 IFI44L 23.3 Yes 1 PLSCR1 8.2 Yes 3
BATF2 4.4 Yes 11 IFI6 5.2 Yes 1 PRSS23 4.7 Yes 11
BST2 7.9 Yes 19 IFIH1 6.8 Yes 2 PSMB9 4.6 Yes 6
C4BPB 10.6 Yes 1 IFIT1 26.7 Yes 10 REC8 4.6 Yes 14
CCL5 5.0 Yes 17 IFIT2 8.4 Yes 10 RPSA 4.5 Yes 3
CLDN1 4.1 Yes 3 IFIT3 21.2 Yes 10 RTP4 8.0 Yes 3
CLDN6 4.4 Yes 16 IFIT5 8.1 Yes 10 S100A16 4.1 Yes 1
CMPK2 4.7 Yes 2 IFITM1 8.8 Yes 11 SAMD9L 8.7 Yes 7
COX7B2 6.7 Yes 4 IFITM2 9.3 Yes 11 SP110 6.1 Yes 2
CST6 11.7 Yes 11 IFITM3 13.4 Yes 11 SPANXA1 26.8 X
CSTA 5.8 Yes 3 IFITM4P 12.7 Yes 6 SPANXB2 50.8 Yes X
CT45A1 18.9 Yes X IGFBP3 6.8 Yes 7 SPANXD 25.3 X
CT45A5 20.7 Yes X IRF7 7.9 Yes 11 SPINK1 5.3 Yes 5
CXCL11 5.3 Yes 4 IRF9 10.7 Yes 14 SRGN 4.7 Yes 10
DDX58 13.2 Yes 9 ISG15 12.2 Yes 1 STAT1 8.1 Yes 2
DDX60 24.6 Yes 4 KRT17 6.9 Yes 17 TAP1 5.6 Yes 6
DDX60L 9.5 Yes 4 KYNU 4.3 Yes 2 TDRD12 12.3 Yes 19
DEFB1 5.1 Yes 8 LAMP3 7.1 Yes 3 TFPI2 4.5 Yes 7
DHRS2 6.8 Yes 14 LEPREL1 4.5 Yes 3 TGFBI 4.0 Yes 5
DHX58 7.1 Yes 17 MMP13 6.2 Yes 11 TKTL1 6.9 Yes X
EPSTI1 5.4 Yes 13 MT1B 7.1 Yes 16 TNFAIP2 8.5 Yes 14
F3 5.1 Yes 1 MT1G 5.8 Yes 16 TPM2 5.3 Yes 9
FHL2 4.3 Yes 2 MT1H 8.6 Yes 16 TRIM22 5.6 Yes 11
FLJ13744 5.4 6 MT1X 9.7 Yes 16 UBD 4.8 Yes 6
FMR1NB 6.8 Yes X MT2A 11.7 Yes 16 UCA1 10.2 Yes 19
FN1 9.7 Yes 2 MX1 25.7 Yes 21 USP18 9.0 Yes 22
FSTL1 4.6 Yes 3 MX2 5.2 Yes 21 VCX 20.5 Yes X
G0S2 8.2 Yes 1 NFE4 9.4 VCX2 12.2 Yes X
GTSF1 6.4 Yes 12 NLRP2 4.5 Yes 19 VCX3A 19.7 Yes X
HCLS1 11.2 Yes 3 OAS1 7.5 Yes 12 VCY 8.5 Yes Y
HERC5 6.1 Yes 4 OAS2 8.4 Yes 12 XAF1 8.3 Yes 17
HERC6 6.5 Yes 4 OAS3 12.9 Yes 12 XK 5.0 Yes X
HLA-C 4.1 Yes 6 OASL 9.1 Yes 12 ZBED2 4.9 Yes 3
*  3.9 fold upregulated in H2170
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We next extrapolated, as was done for the RASSF1 signature earlier, all of our 
immune-related data to primary NSCLC samples in TCGA. We first approached this by 
examining those genes found to be increased by 4-fold or more by 5-Aza-CR in the 
H2170 cell line which harbors the 9-fold increase for IRF7 (Figure 3.4J). The first 
important finding is that in both LUSC and LUAD we find a general pattern of 
concordant lower expression of immune-related genes (Figure 3.8B). Moreover, many of 
these are likely IRF7 targets identified by promoter sequences in PScan analyses, and/or 
according to the literature (Table 3.2). Also, for each histology, there are subgroups with 
especially low expression levels which concordantly cluster to either all the 5-Aza-CR 
responsive genes in H2170 (Figure 3.8B), just the 5-Aza-CR up-regulated genes from 
Figure 3.4C-J (Figure 3.10), or to 5-Aza-CR up-regulated genes enriched in immune-
related pathways listed in Figure 3.4A (Figure 3.8). Importantly, IRF7 has lower basal 
expression, increased transcription start site DNA methylation, and low expression 
tracking with low immune expression subgroups of LUSC (Figure 3.8B & 3.11). 
Interestingly, the IRF suppressor gene, PITX1, is expressed in most LUSC, but has 
transcription start site DNA methylation and lower expression in LUAD (Figure 3.8C & 
3.11). Finally, and importantly, expression levels of PD-L1, the key tumor ligand targeted 
in the anti-checkpoint immunotherapy trials, tracks quite well with the above immune 
evasion signature in both LUSC and LUAD, as especially well visualized in heat maps 
for immune related pathways (Figure 3.11).  
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Figure 3.10. TCGA NSCLC samples cluster into subgroups with concordant low 
expression levels of genes up-regulated by 5-Aza-CR in Figure 3.4C-J. 
TCGA heat map for expression of genes (top panel) from Figure 3.4C-J (shown as panels 
on the Y-axis) that are up-regulated greater than 0.5-fold (log2 scale) in at least one of the 
eight NSCLC cells lines after treatment with 5-Aza-CR compared to mock at day 10. 
Panels beneath show expression of PD-L1, IRF7 and PITX1 with correlating DNA 
methylation heat map plotted exactly as in Figure 3.4C.  
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Figure 3.11. Immune pathways cluster with subgroups of NSCLC defined by 
expression of IRF7 transcription factor targets. 
Left panels are LUSC and right panels are LUAD primary samples. PD-L1, IRF7, and 
PITX1 expression are depicted on the top bar panels by quantile expression. Sample 
ordering is established by unsupervised clustering of TCGA samples based on expression 
levels of IRF7 targets derived from H2170. Sample order is maintained across all other 
bar panels and heat maps demonstrating that subgroups defined by IRF7 transcription 
factor targets cluster tightly with multiple immune pathways. Venn diagrams depict the 
overlap with the IRF7 targets up-regulated in H2170 of the most enriched genes in each 
pathway. A complete table showing the overlaps is available in Table 3.4. That the 
observed clustering pattern is not due to chance is illustrated by using a random set of 25 
genes each in the bottom two panels. All color codes for expression are as per Figure 
3.8B-C. 
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Stress Response 20 - - - - - - - -
Death Genes 1 59 - - - - - - -
KEGG Antigen Processing 
and Presentation
0 1 49 - - - - - -
Immune Tolerance 
Regulation
1 2 13 44 - - - - -
Inflammasome 0 14 0 2 50 - - - -
IRF7 Targets in H2170 0 4 1 1 0 25 - - -
KEGG NFKB Pathway 0 9 0 2 6 0 82 - -
KEGG Toll Like Recepter 
Signaling Pathway
2 3 0 3 5 1 9 33 -
KEGG RIG I Like Recepter 
Signaling Pathway
0 6 1 0 1 3 6 6 22
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All of these above data are potentially highly relevant to recent occurrences for our 
recently completed clinical trial. Five patients who received the epigenetic therapy, after 
progressing, were placed on trials for immunotherapy targeting the immune tolerance 
checkpoint (Juergens et al., 2011). Each patient received medical benefit which can be 
placed into context for this immunotherapy approach alone. In this regard, 85 patients 
with the same stages of LUAD and LUSC as in our epigenetic therapy trial received 
monotherapy with anti-PD-1 or anti-PD-L1 and durable objective response rates (ORRs) 
occurred for 10% of patients for anti-PD-L1 and 18% for anti-PD-1. An additional 12% 
and 7% of patients demonstrated stable disease (SD) of > 24 weeks, respectively 
(Brahmer et al., 2012; Topalian et al., 2012). While these responses are the highest ever 
reported for immunotherapy in advanced lung cancer (Brahmer et al., 2012; Topalian et 
al., 2012), the five patients receiving this immunotherapy after epigenetic therapy (patient 
data in Table 3.5), treated either with anti-PD-1 or anti-PD-L1have all shown treatment 
benefit lasting at least 24 weeks, and three of five have experienced major radiologic 
responses to subsequent immunotherapy, all of which are ongoing from 18 to 24+ months 
(Figure 3.12). Obviously, the true potential of combining epigenetic therapy with 
cytotoxic or immunotherapies warrants follow-up trials, which are soon to start. However, 
these trials could benefit greatly from the laboratory data contained in our present study 
as it provides potential insights into mechanisms that might underlie the above promise 
and a path forward to generate biomarker strategies which can be tested in the upcoming 
validation trial.  
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Table 3.5. Patient data for 5 patients treated with combination epigenetic therapy 
consisting of 5-Aza-CR and Entinostat prior to single agent anti-PD-1 or anti- PD-




Patient 1 2 3 4 5
Gender Male Male Female Female Male
Age 62 62 64 68 62
Histology (mutation, if known) LUAD LUSC LUAD (KRAS) LUSC LUSC
Number of Treatment before 
Epigenetic Treatment
3 1 1 1
Best Response to Any Prior 
Treatment *
SD PR SD PD PR
Duration of Treatment with 5-Aza-
CR & Entinostat prior to Immune 
Treatment (months)
2 2 6 2 8
Best Response to Epigenetic 
Treatment *
PD PD MR PD PR
Type of Immune Treatment Anti-PD1 Anti-PD1 Anti-PD-L1 Anti-PD1 Anti-PD-L1






(ongoing) 8.25 months 8.5 months
Response to Immune Therapy PR (-57%) PR (-73%) PR (-64%) SD (+11%) SD (+18%)
* SD  = Stable Disease
   PR   = Partial Response
   PD  = Progressive Disease




Figure 3.12. Outcomes for five NSCLC patients treated with anti-PD1 immune 
checkpoint inhibitor immunotherapy after epigenetic therapy. 
(A) CT scans for 3 patients who responded to anti-PD1 immune checkpoint therapy. 
Tumor lesions are highlighted by red arrows (Pt.1 with splenic metastasis resolving by 19 
months on immunotherapy; Pt.2 with involved lymph node in left chest and green arrow 
denoting an area of the right lung collapsed behind airway obstruction due to tumor both 
resolving over a 10-month period on immunotherapy; Pt.3 lung parenchymal tumor 
resolving over 21 months on immunotherapy) (B) Spider plot of RECIST measurements 
from serial CT scans over time for 5 patients who received anti-PD1 immune checkpoint 
therapy after epigenetic therapy. A decrease in tumor measurements of 30% or more 
qualifies as RECIST criteria response (green circles). An increase in tumor measurements 
of 20% or more qualifies as disease progression (blue X’s). 24 weeks denoted by the 
dashed vertical line represents the time at which a patients with less than 20% increase in 
tumor measurements are considered stable disease as defined by the published trials of 
anti-PD1 therapy (Brahmer et al., 2012; Pardoll, 2012; Topalian et al., 2012).  
Pre Rx 19 Months
A Pt. 1
Pre Rx 21 Months
Pt. 3
B
Pre Rx 10 Months
Pt. 2
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We must address, lastly, a key issue, concerning mechanisms that may account for all 
of the pre-clinical data we have presented. These are probably quite complex, dose-
related actions of 5-Aza-CR. As we show, the drug induces a cascade of direct and 
indirect effects within pathways. However, this drug is best known for inducing DNA 
demethylation through direct inhibition of the catalytic sites and triggering degradation of 
biologically active DNMTs (Gabbara and Bhagwat, 1995; Santi et al., 1984). We, thus, 
compared findings from NSCLC cell lines to HCT116 colon cancer cells and HCT116 
double knock out (DKO) cells that have been genetically disrupted to give severe haplo-
insufficiency of DNMT1, and complete absence of DNMT3B, which are enzymes for 
DNA methylation maintenance and de novo DNA methylation, respectively (Rhee et al., 
2002). Gene expression alterations in DKO versus wild type HCT116 (Figure 3.13A-H) 
are remarkably similar to the 5-Aza-CR induced changes (Figure 3.4C-J) in NSCLC cells. 
Thus, off target effects of high dose 5-Aza-CR, including incorporation into RNA and 
DNA as an abnormal nucleotide (Stresemann and Lyko, 2008), do not appear to be 
required for many of the drug’s effect that we have defined.  
	   116 
 
 
Figure 3.13. Gene expression alterations in DKO versus wild type HCT116. 
The gene expression differences are given as the log2 ratio of expression in DKO over 
wild type cells (Y-axis) and the gene panels, A-H correspond to panels C-J in Figure 3.4 
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3.5 Discussion 
 
In the present work, we have taken a novel track for deriving pre-clinical 
understanding of tumor cell responses that are potentially highly relevant to emerging 
promise of a drug in the clinic. By matching relevant drug dose in cell lines to not only 
tumor responses in vivo but also to genome-wide DNA methylation and gene expression 
responses, we see robust pathway responses important for the pre-clinical agent effects. 
Then, by matching these profiles to the extensive genomic data in the TCGA project, we 
observe what could prove to be key signatures relevant to primary cancers. 
With respect to the specific drug studied, we derive potentially valuable insight into 
how an agent targeting epigenetic abnormalities in NSCLC may have clinical efficacy. 
Our results are relevant for existing clinical trial data indicating that a regimen employing 
5-Aza-CR may yield patient responses to the therapy alone and/or re-sensitization to 
standard chemotherapies and new forms of immunotherapy. Moreover, we observe the 
possibilities that the pathways and genes which emerge from our data may interact in 
contributing to all of these clinical responses. As noted previously, the clinical responses 
discussed obviously need to be validated in subsequent clinical trials which are about to 
begin. Thus, we will be testing patients with advanced NSCLC of both LUAD and LUSC 
histologies, for continued responses to epigenetic therapy alone and formally to see if we 
extend the promise for sensitization to standard chemotherapy and to immune tolerance 
checkpoint therapy. 
A key issue to mention is that in our clinical trials we have employed the HDAC 
inhibitor Entinostat in combination with 5-Aza-CR (Juergens et al., 2011). This agent 
	   118 
could of course be playing a major role in any patient responses of the types under 
discussion. This drug is known to up-regulate many of the genes we have studied, and 
may be especially involved in host immune responses (Claus et al., 2005; Fonsatti et al., 
2007; Simova et al., 2011). These possibilities must be pursued further in subsequent 
studies, and especially, host immune cell responses will be closely monitored in our 
subsequent clinical trial of anti-PD1 therapy. The HCT116-DKO model has allowed us to 
look at a comparison between a genetic knock out of DNMT’s, the 5-Aza-CR induced 
responses, and responses to the potent HDACi trichostatin (TSA). For essentially all of 
the genes we have examined, the genetic disruption of DNMT’s and 5-Aza-CR treatment 
are the maneuvers which either singularly or most potently induce gene up-regulation in 
the HCT116 tumor cells (data not shown). We now need to extend these data in future 
studies and establish the role of both drugs for host immune responses in addition to 
those within the epithelial tumor cell. 
In summary, the data we present in the present work now give us a targeted approach 
to query, in pre- and post- tumor biopsies, whether events like the status of RASSF1 and 
IRF7 DNA methylation, demethylation, and gene expression changes, plus expression 
changes in all the cell cycle, stem cell, apoptosis, and immune regulation pathways we 
have observed track with any patients benefits which may continue to emerge. If such 
patient efficacy is seen we may be developing a crisp biomarker approach for 
determining which individuals are likely to benefit from the epigenetic therapy 
approaches we are testing in clinical trials. Finally, the gene and pathway responses we 
are observing have important implications for future clinical trial design and provide 
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strong clues as to how to employ drugs like 5-Aza-CR in even more ways to sensitize to 
chemotherapy and targeted agents.  
	   120 
3.6 Materials and Methods 
 
3.6.1 Clinical Data 
Institutional review board approved informed consent signed by each patient allowed 
the collection of clinical data following treatment on trial with epigenetic therapy. 
Relevant data were obtained by chart review. Representative images demonstrating 
responses to therapy were obtained from computed tomography series employed in the 
assessment of patient responses to anti-PD1 or anti-PD-L1 directed immune-checkpoint 
therapy. Assessment of response to treatment was performed by a single reference 
radiologist who employed (RECIST 1.0) to generate measurements for target lesions to 
be followed over the course of therapy. Change in target lesions from baseline (%) is 
calculated by summing the diameter of all target lesions at each radiographic tumor 
evaluation and calculating percentage change at a given time point ([(Target Lesion 
SumTimepoint X/ Target Lesion SumBaseline)-1]*100) 
Though patients were not enrolled in a single, randomized clinical trial to test the 
concept of whether priming with epigenetic therapy augments treatment efficacy of PD-1 
directed immune checkpoint inhibition the outcomes for the 5 patients was statistically 
different from patients receiving immunotherapy alone (p < 0.02, Fisher’s Exact Test) 
and should be taken as preliminary evidence supporting further scientific and clinical 
investigation. 
 
3.6.2 Solid Tumor Xenograft Tumorigenicity Assay 
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The measurements of tumor xenografts was performed exactly as per our previous 
publication (Tsai et al., 2012). Specifically, for this study, NSCLC lines H838, H1299, 
H358, H2170, H358, H460, HCC827, and HCC4006 cells were pretreated with 500 nM 
azacytidine or PBS (Mock) for 72 hr followed by another 7 days in culture without drug. 
Harvested cells were injected (1 × 106) subcutaneously into a single flank of five 4- to 6-
week-old male NOD/SCID mice. Serial tumor measurements were obtained on a weekly 
basis after tumor xenograft injection. 
 
3.6.3 TCGA Samples 
Level 3 RNA-Seq data (Illumina HiSeq RNA-Seq platform, Illumina, Inc., San 
Diego, CA, USA) were downloaded for 353 NSCLC samples (129 LUAD / 224 LUSC) 
and 54 adjacent non-tumor lung tissue samples from the TCGA Data Portal (https://tcga-
data.nci.nih.gov/tcga/). Similarly, level 1 DNA methylation data (Illumina Infinium 
HumanMethylation450 BeadChip, Illumina, Inc., San Diego, CA, USA) were 
downloaded for 353 NSCLC samples (222 LUAD / 149 LUSC) and 74 adjacent non-
tumor lung tissue samples. Among these, data for 174 NSCLC samples (80 LUAD / 94 
LUSC) and 21 adjacent non-tumor lung tissue samples were available on both of the 
above platforms. 
 
3.6.4 RNA-Seq Data Analysis 
We used TCGA level 3 RNA-Seq data that were already normalized and quantified at 
gene levels, and were presented as RPKM values (Reads Per Kilobase per Million 
mapped reads). To construct heat maps: 1) Values of 0 (indicating no reads observed for 
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a gene) in the RPKM data were set to NA; 2) the remaining RPKM values were log 2 
transformed; 3) genes from X and Y chromosomes were removed; and 4) heat maps were 
made using the “heatmap.2” function in “gplots” package from CRAN (Warnes, 2012), 
being centered and scaled in the row direction, and using the default functions for 
computing distance and hierarchical clustering (or being specifically ordered in column 
according to the order of other heat maps). Expression spectrums for individual genes 
were displayed in five quantile intervals following the order of associated heat maps of 
the RNA-Seq data. 
 
3.6.5 Infinium DNA Methylation Data Analysis 
TCGA level 1 DNA methylation data contained the raw binary intensity data files. 
Raw data files were imported into R (http://www.r-project.org) to calculate beta values 
(beta value Infinium = M / [U + M], M: mean intensities of the Methylated bead types, U: 
mean intensities of the Unmethylated bead types), M values (M value Infinium = log 2 [M / 
U]) and detection p-values (calculated by comparing probes to negative control probes to 
determine if signals are significantly different from the background) using the 
“methylumi” package from Bioconductor (Davis et al., 2012). beta values and M values 
for probes with detection p-value > 0.05 were considered not significantly different from 
background and were masked as NA. 
TCGA methylation data were first assessed for batch effects by principle component 
analysis (PCA) on the M values. To accomplish this, data points from X chromosome and 
Y chromosome as well as data points that are associated with SNPs (Single Nucleotide 
Polymorphisms) were removed, and the first two principle components are used for 
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plotting (Figure 3.14). To better illustrate the relationship between different batches, plots 
were enhanced by displaying the centroid of each batch (Figure 3.14C & D), where 
centroid was calculated by taking the mean of all the samples in the corresponding batch. 
From the analysis we can conclude that there is distinct difference in TCGA methylation 
data between NSCLC samples and adjacent non-tumor lung tissue samples, as well as 
between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) samples, 
and there were no significant batch effects throughout the studies (Figure 3.14). 
Spearman’s correlation coefficients between methylation (beta value of probe, 
Illumina Infinium HumanMethylation450 BeadChip) and gene expression (RPKM value 
of gene, Illumina HiSeq RNA-Seq platform) were calculated using TCGA samples with 
available data on both platforms. For a particular gene, only methylation probes that have 
a negative Spearman’s correlation coefficient and a adjusted p-value (FDR) for the 
coefficient < 0.01 were considered informative and their relative distances to the 
corresponding transcriptional start site (TSS) of the genes were calculated from genomic 
coordinates obtained from the UCSC genome browser (http://genome.ucsc.edu). Heat 
maps of the M values of informative probes were made using the “heatmap.2” function in 
“gplots” package from CRAN (Warnes, 2012), being centered and scaled in the row 
direction, and ordered according to the associated heat maps of the RNA-Seq data in 
column and to the relative distances to TSS in row.  
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Figure 3.14. PCA analysis of TCGA level 1 DNA methylation data. 
(A) Analysis of all samples indicates a distinct separation of NSCLC samples (red) from 
the adjacent non-tumor tissue samples (green). (B) When the analysis is performed only 
on the NSCLC samples, a distinct separation was observed between LUAD (red) and 
LUSC (orange). PCA analysis of only LUAD samples (C) and LUSC (D) indicates 
limited batch effects, which are obvious by the close distribution pattern of the centroids 
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For in vitro DNA methylation values, DNA was extracted from cell lines that were 
either untreated or treated with 5-Aza-CR at day 3, at the end of treatment, and day 10 (7 
days post end of treatment) and analyzed by the Illumina Infinium 
HumanMethylation450 BeadChips (Illumina, Inc., San Diego, CA, USA). Raw data were 
imported into R using the “methylumi” package from Bioconductor (Davis et al., 2012). 
Data points for probes with detection p-value > 0.05 were masked as NA. Δ beta values 
(Δbeta  value=beta  valueAza-beta  valueMock) were calculated and used to make boxplots. 
Heat maps were made similarly like those for the TCGA data using informative probes 
defined by the TCGA data. 
 
3.6.6 Expression Microarray Data 
For in-vitro RNA extracted from cell lines treated with 5-Aza-CR, analyses were 
done at exactly the same time points as for DNA methylation above. Analyses from wild 
type colon cancer, HCT116 cells, and genetic knockout counterparts for DNA 
methyltransferases (DKO cells) were also performed. Expression microarrays were 
carried out using Agilent Human 4× 44K expression arrays (Agilent Technologies, Santa 
Clara, CA, USA, Cat#: G4112F). Within-array and between - array normalization was 
performed using Loess and Aquantile normalization, respectively (Smyth and Speed, 
2003). Median of the M values (M value Expression = log 2 [5-Aza-CR / Mock] OR log 2 
[DKO / HCT116]) was determined for multiple probes associated with the same gene. 
 
3.6.7 Gene Set Enrichment Analysis (GSEA) 
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For each of the eight lung cancer cell lines (H838, H1299, H358, H1270, A549, 
H460, HCC4006, HCC827) a ranked gene list was created (genes were sorted by 
decreasing M value). These eight ranked gene lists were entered in the GSEA tool 
(Subramanian et al., 2005) and the enrichment of both Kegg (Goto et al., 1997) and 
Reactome (Joshi-Tope et al., 2005) pathways in these lists was calculated (default 
parameters). A gene set was selected when it was enriched in any of the eight cell lines (p 
value < 0.05 and false discovery rate < 0.25). The normalized enrichment scores (NES) 
for the gene sets in each cell line were used to create the heat maps. When a certain gene 
set was not significant in a cell line, it was assigned a NES of 0. 
 
3.6.8 Transcriptional Factor Analysis 
Expression and methylation data were analyzed to find genes whose re-expression 
was linked to demethylation after 5-Aza-CR treatment. Genes were selected based on a 
set of cut-offs, both for the methylation and expression values: A gene was considered to 
be re-expressed when at day 3 or day 10 the median M value of all the probes linked to 
that gene was higher than 0.5. Infinium probes were analyzed separately at their distances 
from the transcription start site for each gene examined. For a probe to be called 
demethylated, it had to have a beta value higher than 0.5 in the mock treatment and the 
difference in beta value between mock and 5-Aza-CR treatment had to be higher than 
0.25. Only probes that were associated with a CpG island and that were located within 
1000 bp upstream and 1000 bp downstream of the transcription start site were used in the 
analyses. The probes that passed these filters were validated using the TCGA methylation 
and expression data (see the definition of informative probes in the “Infinium DNA 
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Methylation Data” section of Methods). Only genes that had an expression-methylation 
correlation value < -0.25 and a false discovery rate < 0.05 were retained. 
To better understand the biological implications of the re-expressed genes, the gene 
lists were searched for transcription factors. Two human transcription factor lists obtained 
from Ravasi et al. (Ravasi et al., 2010) and Vaquerizas et al. (Vaquerizas et al., 2009) 
were combined and the resulting list was matched to the lists of demethylated and re-
expressed genes. The targets of IRF7 from the list of genes that are 4-fold or more up-
regulated in H2170 by 5-Aza-CR were similarly identified using the 
TranscriptomeBrowser database (Ravasi et al., 2010; Vaquerizas et al., 2009). 
 
3.6.9 Flow Cytometry Methods (FACS) 
Frozen cells were thawed in 37 degrees celcius and washed once with flow-washing 
buffer. Aliquots of single-cell suspension were then stained with fluorescent-labeled 
antibodies for 15 mins at room temperature. Each sample was washed twice and 
resuspended in flow-washing buffer and analyzed by FACSCalibur. The following 
antibodies were used: CD274 (12-5983-42 Ebiosciences), HLA abc (12-9983-42 
Ebiosciences), CD276 (331606 Biolegend), CD119 (558934 BD), B2 microblogumin 
(551337BD), CD58 (555921BD). 
 
3.6.10 PSCAN 
PSCAN (http://159.149.160.51/pscan/) (Zambelli et al., 2009) is an online software 
tool that predicts the association of user-defined gene-lists with transcription factors by 
scanning promoter sequences of co-regulated or co-expressed genes looking for over- or 
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under-represented motifs. RefSeq IDs of the gene lists were obtained from BioMart 
(http://www.biomart.org/) and analyzed in PSCAN. Scanned promoter region was -450 to 
+50 base pairs around the transcription start site and employing TRANSFAC as the 
database for co-regulated or co-expressed genes.  
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Conclusions and future directions 
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The majority of cancers are age-related, caused and/or facilitated by numerous 
accumulating genetic and epigenetic alterations in response to stimuli experienced during 
aging, such as tobacco exposure, environment pollution, stress and chronic inflammation. 
As society advances and the people’s average lifespan greatly improves, cancer has 
become one of the major causes of death in humans. It is of great urgency to understand 
the underlying mechanisms of cancer initiation and progression, in order to develop more 
effective strategies to improve cancer prevention, early detection and treatment.  
In recent years, epigenetics has been given more and more attention in the cancer 
research field due to its potentially extensive role in all aspects of cancer and its 
appealing nature of being relatively easy to reverse by pharmacological agents. Despite 
the enormous and growing number of papers published every year, we have only scraped 
the tip of the iceberg in our full understanding of the epigenetic changes in cancer and 
their causes. Fortunately, with the development of novel technologies and advancement 
in new analysis methods, especially the widespread use of various genomic-based and 
bioinformatic approaches, we are able to take cancer epigenetic research to a new level.  
In this thesis, our studies have taken advantage of these advances to provide further 
insight into the origins of epigenetic abnormalities in human cancer, and to apply this 
knowledge to the translational goal of bringing epigenetic therapy to the biggest cancer 
killer, advanced lung cancer. The conclusions we have reached can be summarized as 
follows. 
In chapter 2, we used a genome-wide chromatin immunoprecipitation approach 
together with studies of gene expression and DNA methylation to investigate whether the 
cell stress of rapidly increasing reactive oxygen species, and resultant oxidative damage 
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to DNA and/or chromatin, induces molecular mechanisms that alter the epigenome. 
These studies identified that the above stress can, within 30 minutes, trigger oxidative 
damage-induced increase in size and abundance of, and tightening to chromatin of key 
constituents of, a pre-existent, transcription repressing, complex containing DNA 
methyltransferases and members of the cancer specific polycomb repressive complex, 
PRC4. This complex moves from GC poor genomic regions to damage sites within GC 
rich ones in gene promoter regions. These findings provide connections between 
oxidative damage, transient silencing of genes perhaps as a protective mechanism during 
repair of DNA damage, and reveal how key genes may be vulnerable during these 
processes to evolve abnormal DNA methylation. The findings, plus work in a mouse 
model of colon inflammation, suggest how the leading cancer-risk state, chronic 
inflammation, may induce key epigenetic changes which may play a key role in tumor 
initiation and facilitate malignant transformation. 
Extended studies will be required to further understand the nature of this oxidative 
damage-induced silencing complex. We must learn more about how it is assembled and 
recruited to chromatin and why it preferentially targets transcriptionally active and GC 
rich genomic regions after H2O2 exposure. Some evidence indicates that targeting of the 
complex is associated with the distribution of DNA damage sites, thus linking its 
formation and positioning to chromatin accessibility, types of damage, and the fact that 
guanine is the most easily oxidized of the four deoxyribonucleosides (Steenken, 1997). 
Furthermore, an in vitro chronic oxidative damage model is needed to examine how the 
observations we have defined occur over time and how we can extrapolate our studies to 
in vivo events for chronic inflammation models. 
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In chapter 3, we used a genomic-based approach, and bioinformatic methods, to 
explore what molecular mechanisms might underlie early promising responses of patients 
with advanced, non-small cell lung cancer (NSCLC) to therapies employing the DNA 
demethylating agent, 5-aza-cytidine (5-Aza-CR). By profiling genome-wide gene 
expression and DNA methylation responses to 5-Aza-CR treatment for eight NSCLC cell 
lines, we observed in most cell lines a complex multi-faceted up-regulation, including 
hundreds of genes, of immune-related pathways. Moreover, using the obtained molecular 
signature, we have been able to specifically query hundreds of primary NSCLC samples 
in the Cancer Genome Atlas project for how basal expression of these genes groups these 
cancers. Our findings suggest, especially in the setting of the above patient responses, 
that epigenetic therapy may sensitize such individuals to immune checkpoint blockade at 
least, in part, by shifting the tumor cells away from an immune evasion state towards 
enhanced immune recognition.  
A critical aspect of the work, in addition to providing for understanding of the 
molecular mechanisms underlying the above sensitization, is the potential of the findings 
to develop biomarker strategies to predict which patients with NSCLC may benefit the 
most from the therapeutic approach. A larger clinical trial is now just underway in which 
these strategies can now be tested.  
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